Decremental Follicle-Stimulating Hormone and Single Dominant Follicle Selection in the Human by Santbrink, E.J. (Evert) van
DECREMENTAL FOLLICLE-STIMULATING 
HORMONE AND SINGLE DOMINANT FOLLICLE 
SELECTION IN THE HUMAN 
DALEND FOLLIKEL-STIMULEREND HORMOON EN 
SELECTIE VAN EEN DOMINANTE FOLLIKEL BIJ DE 
MENS 
The publication of this thesis has been facilitated by an 
educational grant from NV Organon 
DECREMENTAL 
FOLLICLE-STIMULATING HORMONE 
AND SINGLE DOMINANT FOLLICLE 
SELECTION IN THE HUMAN 
DALEND FOLLIKEL-STIMULEREND 
HORMOON EN SELECTIE VAN EEN 
DOMINANTE FOLLIKEL BIJ DE MENS 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR 
AAN DE ERASMUS UNIVERSITEIT ROTTERDAM 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR. P.W.C. AKKERMANS M.A. 
EN VOLGENS BESLUIT VAN HET COLLEGE VOOR PROMOTIES. 
DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP 
WOENSDAG 15 APRIL 1998 OM 11.45 UUR 
DOOR 
EVERT JAN PIETER VAN SANTBRINK 
GEBOREN TE ROTTERDAM 
The Parthenon Publishing Group 
International Publishers In Medicine} Science & Technology 
NEW YORK LONDON 
Published in the UK by 
The Parthenon Publishing Group Ltd. 
Casterton Hall, Carnforth, 
Lanes, LA6 2LA, England 
Published in the USA by 
The Parthenon Publishing Group 
One Blue Hill Plaza, 
PO Box 1564, Pearl River, 
New York 10965 USA 
Copyright © EJP van Santbrink, 1 998 
ISBN: 1-85070·046-X 
The work presented in this thesis was performed in the Division of 
Reproductive Medicine (Head Prof. Dr B.C.J.M. Fauser), Department of 
Obstetrics and Gynecology, Dijkzigt Academic Hospital and Erasmus 
University, Rotterdam, The Netherlands. 
The author was in part supported by 'Stichting Voortplantingsgeneeskunde 
Rotterdam' . 
Some parts of this publication have been published previously and have been 
reproduced with permission from the publishers: the American Society for 
Reproductive Medicine (van Santbrink, E.J.P., Hop, w.e., van Dessel, 
H.J.H.M., de Jong, F.H. and Fauser, B.C.J.M. (1995) Decremental 
follicle-stimulating hormone and dominant follicle development during the 
normal menstrual cycle. Fertil Steril64, 37-43, and van Santbrink, E.J.P., 
Hop, W.C. and Fauser, B.C.J.M. (1997) Classification of normogonadotropic 
anovulatory infertility: polycystic ovaries diagnosed by ultrasound versus 
endocrine characteristics of polycystic ovary syndrome. Fertil Steril 67, 
453-458). The European Society for Human Reproduction and Embryology 
(van Santbrink, E.J.P., Donderwinkel, P.F.J., van Dessel, H.J.H.M. and 
Fauser, B.C.J.M. (1995) Gonadotrophin induction of ovulation using a 
step-down dose regimen: single-center clinical experience in 82 patients. 
Hum Reprod 10, 1048-1053), and the Endocrine Society (van Santbrink, 
E.J.P. and Fauser, B.C.J.M. (1997) Urinary follicle-stimulating hormone for 
normogonadotropic clomiphene-resistant anovulatory infertility: prospective, 
randomized comparison between low dose step-up and step-down dose 
regimens. J C!in Endocrino! Metab, 82, 3597-3602). 
First published 1998 
No part of this book may be reproduced in any form, by print, phatoprint, 
microfilm or any other means without written permission from the author. 
Niets uit deze uitgave mag worden verveelvoudigd en/of apenbaar gemaakt 
door middel van druk, fatacapie, microfilm of welke andere wijze oak zander 
vaarafgaande schriftelijke taestemming van de schrijver. 
Cover design: Bas Barnasconi, Strijen, The Netherlands. 
Typeset by Martin Lister Publishing Services, Carnforth, UK 
Printed and bound by Butler & Tanner Ltd., Frome and London, UK 
PROMOTIECOMMISSIE 
PROMOTOR 
OVERIGE LEDEN 
Prof. Dr B.C.J.M. Fauser 
Prof. Dr D.T. Baird 
Prof. Dr H.J.T. Coelingh Bennink 
Prof. Dr F.H. de Jong 
Prof. Dr Th.J.M. Helmerhorst 

Contents 
Chapter 1 Introduction 
1.1 History and definition of study objectives 1 
1.2 Ovarian physiology 3 
1.2.1 Morphology of the human ovary 3 
1.2.2 Gonadotropin-independent early follicle development 4 
1.2.3 Gonadotropin-dependent advanced follicle development 5 
1.3 Dynamics during the normal menstrual cycle: 
the endocrine concept 7 
1.4 Intra-ovarian modification of FSH action: 
the autocrinelparacrine concept 8 
1.5 Gonadotropin induction of ovulation 9 
1.6 Outline ofthe thesis: studies and objectives 12 
Chapter 2 The normal menstrual cycle 
2.1 General introduction 13 
2.2 Decremental follicle-stimulating hormone and 
dominant follicle development in the normal 
menstrual cycle 14 
2.2.1 Introduction 14 
2.2.2 Patients and methods 15 
2.2.3 Results 16 
2.2.4 Discussion 21 
Chapter 3 Polycystic ovary syndrome 
3.1 General introduction 25 
3.2 Classification of normogonadotropic anovulatory 
infertility: polycystic ovaries diagnosed by 
ultrasound versus endocrine characteristics of 
polycystic ovary syndrome 25 
3.2.1 Introduction 25 
3.2.2 Patients and methods 26 
3.2.3 Results 28 
3.2.4 Discussion 31 
3.3 Predictors of follicle development in gonadotropin 
induction of ovulation using a decremental 
dose regimen 36 
DECREMENTAL FSH AND SINGLE DOMINANT FOLLICLE SELECTION IN THE HUMAN 
3.3.1 Introduction 36 
3.3.2 Patients and methods 37 
3.3.3 Results 39 
3.3.4 Discussion 39 
Chapter 4 Gonadotropin induction of ovulation 
4.1 General introduction 45 
4.2 Gonadotropin induction of ovulation using a 
step-down dose regimen: single-center clinical 
experience in 82 patients 46 
4.2.1 Introduction 46 
4.2.2 Patients and methods 47 
4.2.3 Results 49 
4.2.4 Discussion 52 
4.3 Urinary follicle-stimulating hormone for 
normogonadotropic clomiphene-resistant 
anovulatory infertility: prospective, randomized 
comparison between low-dose step-up and 
step-down dose regimens 56 
4.3.1 Introduction 56 
4.3.2 Patients and methods 57 
4.3.3 Results 59 
4.3.4 Discussion 65 
Chapter 5 General Discussion and Conclusions 69 
Chapter 6 References 73 
Chapter 7 SummarylSamenvatting 89 
Chapter 8 Publications 95 
Chapter 9 Curriculum vitae auctoris 99 
Chapter 10 Acknowledgements 101 
AD 
BMI 
CRA 
DHEAS 
E2 
FAI 
FSH 
GnRH 
hCG 
HMG 
im 
IRMA 
iv 
IVF 
LH 
OHSS 
P 
PCO 
PCOS 
pFSH 
RIA 
sc 
SO 
SHBG 
T 
TSH 
TVS 
WHO 
List of Abbreviations 
androstenedione 
body mass index (= weight I height2) 
clomiphene-citrate resistant anovulation 
dehydroepiandrosterone sulphate 
17p-estradiol 
free androgen index (= T x 100 I SHBG) 
follicle-stimulating hormone 
gonadotropin releasing hormone 
human chorionic gonadotropin 
human menopausal gonadotropin 
intramuscular 
immunoradiometric assay 
intravenous 
in-vitro fertilization 
luteinizing hormone 
ovarian hyperstimulation syndrome 
progesterone 
polycystic ovaries 
polycystic ovary syndrome 
purified urinary follicle-stimulating hormone 
radioimmunoassay 
subcutaneous 
standard deviation 
sex-hormone binding globulin 
testosterone 
thyroid stimulating hormone 
transvaginal sonography 
World Health Organization 

1 
Introduction 
1.1 HISTORY AND DEFINITION OF STUDY OBJECTIVES 
One of the earliest known anatomical descriptions of the ovaries is 
produced by Soranus of Ephesus (AD 98-138) who had been studying in 
Alexandria and practiced in Rome. During the following Middle Ages, no 
substantial progress was made regarding reproductive anatomy until 
Leonardo da Vinci (1452-1519), who accurately drew the anatomy of 
the human uterus and ovaries. In the 16th century, the University of Padua 
was an important center of research concerning human anatomy, and pro-
duced famous names like Vesalius and Fallopius. Vesalius (1515-1564) 
described the hypophysis as the 'glandula pituitaria cerebri excipiens' and 
was the first to recognize follicles in the human ovary. Reinier de Graaf 
(1641-1673), a Dutch physician born in Delft, was the first to describe 
the 'female testis' containing the ovarian follicles. Subsequently, investi-
gators referred to the mature dominant follicle as the 'Graafian follicle'. In 
the beginning of the 20th century animal studies were conducted in which 
pituitary extracts and urine of pregnant women were injected into rats 
(Smith and Engle, 1927; Aschheim and Zondek, 1927). These animal 
studies resulted in recognition of two pituitary hormones (luteinizing 
hormone [LH] and follicle-stimulating hormone [FSH]) with different action 
in the ovary (Fevold et al., 1933). It also became clear that urine of 
pregnant women contained predominantly a luteinizing hormone of pla-
cental origin, whereas urine of climacteric women could induce follicle 
growth in the ovary (Leonard and Smith, 1934). When it finally became 
possible to extract gonadotropins from pregnant mare serum, a problem 
in clinical application arose: anti-gonadotropin antibody formation. A 
proper way of extracting the FSH-like substance from the urine of 
postmenopausal women was finally proven to be gel-electrophoresis 
(Borth at al., 1957). This purification technique facilitated the production 
of human gonadotropins and its wide-scale clinical use as treatment for 
patients with oligo- or amenorrhea. Initially, detailed knowledge regarding 
the structure and function of the ovary was derived from morphological 
studies, while the introduction of pelvic ultrasonography (Hackeloer at al., 
1979), made it possible to study the dynamics of ovarian follicle develop-
1 
DECREMENTAL FSH AND SINGLE DOMINANT FOLLICLE SELECTION IN THE HUMAN 
ment in vivo. Although this new imaging technique represented a major 
step to a better understanding of the dynamics of follicle growth it was 
not until transvaginal ultrasonography was introduced, allowing the use 
of high frequency probes in close proximity to the ovaries, that follicles as 
small as 2 mm in diameter could be visualized (pache et al., 1990). On the 
other hand, development of steroid and peptide assays in serum or 
follicular fluid, and in vitro cultures of human ovarian cells increased our 
knowledge of endocrine and paralautocrine factors regulating follicle 
development in the human ovary (Schoot et al., 1 g92a; Fauser et al., 
1995). 
Anovulation represents a major cause of female infertility. Menstrual 
cycle disturbances usually are a reflection of hormonal imbalance. Patients 
presenting with oligomenorrhea or amenorrhea are categorized by the 
WHO (World Health Organization Manual, 1993) into 3 classes, based 
upon serum hormone assays in peripheral blood: Class I, hypogonadotropic 
hypoestrogenic anovulation; Class II, normogonadotropic normoestro-
genic anovulation; and Class III, hypergonadotropic hypoestrogenic anovu-
lation. Important clinical conditions include premature ovarian failure (Class 
III), as well as chronic anovulation in patients presenting with serum FSH 
and estradiol in the normal range, polycystic ovary syndrome (PCOS). 
PCOS, the most common anovulatory disorder in women, is often 
characterized by hirsutism, obesity and oligo- or amenorrhea together with 
disrupted follicle growth in enlarged ovaries, raised serum concentrations 
of circulating androgens and elevated serum LH concentrations. Because 
not all criteria are mandatory, the PCOS patient group is very heterogene-
ous. This may be due to the fact that multiple defects described in the 
PC OS population may result in a similar endpoint: polycystic ovaries. The 
first description by Stein and Leventhal in 1935 (Stein and Leventhal, 
1935), was based upon a specific medical history and characteristic 
findings upon physical examination. However, the major finding was the 
polycystic morphology of the ovaries: 'two to four times the normal size, 
often maintaining their original shape, but sometimes globular or flattened 
like an oyster. Cortex was hypertrophied, tunica was thickened, tough, 
and fibrotic. Cysts were follicular cysts nearly all confined to the cortex, 
and contained clear fluid. There were from 20 to 100 in each ovary, varying 
in size from 1 mm to about 15 mm, rarely larger. The color of the ovary 
was oyster-gray with bluish areas where the cysts were superficial'. More 
recently, diagnosis of PCOS was merely based on clinical symptoms and 
biochemical parameters. At present, some investigators apply just a single 
biochemical marker for PCOS diagnosis, such as elevated serum LH 
concentration, "whereas others use only sonographic parameters or a 
combination of these two. Presently, most clinical investigators seem to 
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consider the ultrasound appearance of polycystic ovaries of reduced 
significance for PCOS diagnosis. This approach could be criticized on the 
basis of the historical description of the syndrome, as mentioned above. 
Correct and strict diagnosis of PCOS and division in subgroups may be 
relevant because of its possible future implications regarding decreased 
pregnancy chances, augmented complication rates during induction of 
ovulation (prediction of treatment outcome), and increased long-term 
health risks (for instance cardiovascular disease or diabetes). 
Induction of ovulation using exogenous gonadotropins in women 
presenting with chronic anovulation is a widely used treatment modality 
since the 1960s. The great majority of anovulatory patients presently 
treated with gonadotropin preparations comprise normogonadotropic 
anovulatory infertile patients (WHO group II) who failed to ovulate (or 
conceive) during previous anti estrogen medication. Although gonado-
tropin therapy has been shown to be fairly successful in terms of ovulation 
rates (reported in literature between 60-1 00%) and cumulative pregnancy 
rates (reported between 20-75 %), complication rates are high. Major 
complications include ovarian hyperstimulation (Navot et al., 1992), 
multiple pregnancies (Derom et al., 1993) and a high incidence of early 
pregnancy wastage (Shoham et al., 1991). 
In this thesis we would like to focus on patients suffering from 
normogonadotropic anovulatory infertility (WHO, class II) and normo-ovu-
latory controls. This concerns a major proportion of the infertility popula-
tion (20-25%). The objective of this thesis is to generate more insight 
into (patho)physiological mechanisms concerning dynamics of follicle 
growth in the human ovary, using frequent transvaginal ultrasonography 
(TVS) combined with hormonal serum assays in peripheral blood. The 
process of follicle recruitment and selection will be closely studied during 
the follicular phase of the normal menstrual cycle and during induction of 
ovulation using gonadotropins, whereas the role of decreasing serum FSH 
concentrations will be especially evaluated. 
1.2 OVARIAN PHYSIOLOGY 
1.2.1 Morphology of the human ovary 
During the second month of fetal life differentiation of the indifferent 
gonads takes place. Three different regions develop: the rete ovarii or 
hilum, the central medullary portion and an outer cortical portion. The hilum 
contains nerves, blood vessels and cells that secrete steroid hormone; the 
cortical epithelium consists of an unicellular layer of cuboidal or squamous 
cells and the inner part contains stroma (connective tissue, contractile 
cells and interstitial cells) and immature germ cells - follicles - enclosed 
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in cellular complexes. Between weeks 4 and 6 of gestation the primordial 
germ cells have migrated from the primitive ectoderm at the caudal end 
and the yolk sac to the gonadal sites. During their movement they begin 
their proliferation. By the sixth week, on completion of the indifferent state, 
these primordial germ cells have multiplied by mitosis to a total of 10000. 
At 6-8 weeks, the first signs of ovarian differentiation are reflected in the 
rapid mitotic multiplication of germ cells, reaching 6-7 million oogonia by 
16-20 weeks (Baker et a/., 1963). This represents the maximal oogonal 
content of the gonad. From this point in time germ cell content will 
irretrievably decrease until, some 50 years later, the store of oocytes will 
finally be exhausted. The oogonia are transformed to oocytes as they enter 
the first meiotic division and arrest in prophase. This process begins at 
11-12 weeks, perhaps in response to factors produced by the rete ovarii. 
Progression of meiosis to the diplotene stage is accomplished throughout 
the rest of pregnancy and completed by birth. There is a temporary arrest 
in oocyte development, characterized by an oocyte in prophase of the first 
meiotic division enveloped by a single layer of granulosa cells surrounded 
by a basement membrane; this is called the primordial follicle. 
1.2.2 Gonadotropin-independent early follicle development 
A continuous flow of primordial follicles from a resting to a growing stage 
can be observed throughout life. During the first period, follicle depletion 
starts at a very high rate, and approximately 2 million primordial follicles 
remain at birth (Peters, 1979). After birth this process slows down. When 
reproductive life starts at menarche, approximately 0.5 million primordial 
follicles are present (Hillier et a/., 1981). During the reproductive period 
follicle-loss takes place at a fixed-rate of approximately 1000 follicles per 
month, accelerating beyond the age of 35 until no more follicles are left 
around menopause (Faddy et a/., 1992; Gougeon, 1993). Factors involved 
in regulation of primordial follicle growth are still largely unknown. Once 
follicles are stimulated to grow they can either become dominant follicles 
and ovulate or become atretic. Follicles are present in the ovary at different 
stages of development with different sizes at any point during the 
menstrual cycle (Gougeon, 1986). 
The primordial follicle is characterized by an oocyte in the prophase of 
the first meiotic division, surrounded by a layer of granulosa cells. Initiation 
of growth results in growth of the oocyte and granulosa cell proliferation 
(primary follicle). The secondary cell stage involves a division of stroma in 
a theca extern a and a theca interna. Theca interna cells exhibit LH receptor 
activity early on (Channing et a/., 1973). During the development of an 
antral-cavity, granulosa cells containing FSH-receptors have been ob-
4 
INTRODUCTION 
served, as cumulus cells surrounding the oocyte and cells bordering the 
basement membrane (Gougeon, 1993). It remains controversial whether 
or not pre-antral follicle development is totally independent from FSH 
(Oktay et al., 1997). After antrum formation has occurred, FSH is needed 
for ongoing follicle maturation although the exact time of initiation of 
gonadotropin-dependent follicle maturation is still uncertain. Complete 
follicle maturation takes at least 85 days (Gougeon, 1996). In a lifetime, 
only 400 follicles reach full maturation and ovulate, leaving the remaining 
follicles to a process referred to as apoptosis ('programmed cell-death'): 
Survival factors suppressing this process are gonadotropins and growth 
factors (Billig et al., 1993; Hsueh et al., 1994), while oxidative stress 
induces atresia (Tilly et al., 1995). FSH decreases apoptosis in granulosa 
cells obtained from hypophysectomized rats (Billig et al., 1994) and 
prevents apoptotic changes of cultured preovulatory follicles (Chun et al., 
1994). 
1.2.3 Gonadotropin-dependent advanced follicle development 
Ongoing follicle growth from the antral stage is not possible without 
gonadotropins. Both gonadotropins, LH and FSH produced by the anterior 
pituitary, have a synergistic action during follicle development. Theca cells 
are stimulated by LH to convert cholesterol to androstenedione (AD) and 
testosterone (T) by cytochrome p450 oxidases and 3~-OH-steroid dehy-
drogenase, whereas granulosa cells aromatase activity (cytochrome p450 
aromatase) is induced by FSH and converts these androgens (AD and T) 
to estrone and estradiol (Ez). The concept of two different cell-types (granulosa and theca cells) and two hormones (LH and FSH) necessary to 
convert cholesterol to estrogens is referred to as the 'two-cell, two-gon-
adotropin' theory. FSH enhances aromatase activity in granulosa cells, 
induces LH and increases FSH receptor formation and stimulates general 
cell functions such as DNA and protein synthesis (Hsueh et al., 1989). 
Two theories are held responsible for the development of a single 
ovarian follicle (Figure 1): the 'FSH-threshold' (Brown, 1978; Schoemaker, 
1993) and 'FSH-window' (Baird, 1987; Fauser et al., 1993a; Fauser, 
1994) theory. During the luteo-follicular transition when FSH concentra-
tions start to rise, a cohort of 'receptive' follicles is recruited. Each 
individual follicle in the cohort of recruited follicles has its own specific 
FSH-threshold that should be surpassed to start gonadotropin dependent 
pre-ovulatory growth. In case the FSH-threshold is not surpassed these 
follicles will go into atresia. The FSH-threshold of a given follicle is not 
fixed but dependent on its developmental stage. The time-period during 
which the FSH-threshold is surpassed, the FSH window, determines the 
5 
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Human follicle development 
- FSH threshold/window concept-
o 
c 
8 
J: 
12 
E I recruitment selection dominance 
: "1/1,.,... ... ! ~ I.~".) 
:g 
luteD-follicular transition 
Figure 1 Schematic representation of the intercycle rise in serum FSH concen-
trations (FSH threshold/window concept), and follicle growth dynamics (recruit-
ment, selection, and dominance) during the follicular phase of the normal 
menstrual cycle. [Reproduced with permission from Fauser, B.C., and van 
Heusden, A.M. (1997a). Manipulation of human ovarian function. Endocr Rev 
18,71-106J. 
number of follicles that are recruited to start preovulatory growth. The 
moment the follicle begins preovulatory development (dominance) it will 
gradually become less dependent on FSH and will start to produce large 
amounts of E2. Plasma E2 and inhibin B concentrations rise and sub-
sequently serum FSH concentrations decrease while follicle growth con-
tinues at a constant rate until ovulation takes place. Proof of the concept 
that throughout the menstrual cycle recruitable follicles are present, has 
been delivered by previous human studies in which the dominant follicle 
has been removed at the end of the follicular phase, or luteectomy in the 
luteal phase was performed resulting in new follicle recruitment and 
subsequent ovulation (Nilsson et al., 1982; Araki et al., 1983; Baird et al., 
1984). Exact mechanisms underlying selection of the dominant follicle and 
subsequent monofollicular growth are still unknown, but diminished 
stimulation of non-dominant follicles by relatively low FSH concentrations 
in combination with local upregulation of FSH action in the dominant follicle 
might play an important role (Hodgen, 1982). 
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Human follicle development 
- follicular phase of the mellstrual cycle -
Q) 
c: 
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selection of a single 
dominant follicle 
7 14 (days) 
Figure 2 Schematic representation of patterns of serum FSH and E2 concen-
trations, and gonadotropin dependent follicle growth, resulting in selection of 
a single dominant follicle during the follicular phase of the normal menstrual 
cycle. 
1.3 DYNAMICS DURING THE NORMAL MENSTRUAL CYCLE: 
THE ENDOCRINE CONCEPT 
During the luteo-follicular transition, a rise in serum FSH is induced on the 
12th day after the preceding LH-surge (Hall et al., 1992) by decreasing 
corpus luteum steroid production. Selection of a cohort of follicles takes 
place, referred to as 'recruitment' (Goodman et al., 1983), when FSH 
surpasses its threshold. From this cohort of follicles selection of a single 
dominant follicle takes place. This process may be regulated by decreasing 
serum FSH concentrations in combination with increased sensitivity for 
FSH of the selected follicle (Figure 2). FSH stimulation of the selected 
follicle may be modulated by FSH isoforms (Chappel, 1995; Fauser et al., 
1997), interference with FSH receptor binding, or postreceptor signal 
transduction (Padmanabhan et al., 1988; Fauser, 1996). The dominant 
follicle starts to produce E2 from a 10 mm stage (Hillier et al., 1980; van 
Dessel et a/., 1 996). Serum E2 concentrations rise and mediate negative 
feed-back at the pituitary and hypothalamic level, resulting in a further 
decrease of serum FSH concentrations. The role of inhibin in dominant 
follicle selection is still unclear, although it may be proposed that the rapid 
rise in inhibin B just after the intercycle FSH rise, which shortens the 
duration of the FSH-rise (narrows the window), is crucial for single 
dominant follicle development (Groome et al., 1996). Whereas the domi-
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nant follicle becomes less dependent on FSH and continues to grow 
(van Santbrink et a/., 1995a), the FSH threshold will not be surpassed for 
less mature follicles from the recruited cohort resulting in atresia. Induction 
of the LH surge by increasing serum E2 concentrations (Fritz et a/., 1992), 
results in ovulation and formation of the corpus luteum. Production of 
progesterone and E2 by the corpus luteum inhibits gonadotropin synthesis 
by the pituitary, but when the corpus luteum undergoes atresia in the 
absence of pregnancy a new menstrual cycle is initiated. 
Various forms of FSH are synthesized and secreted by the anterior 
pituitary, on the basis of differences in oligosaccharide structure of these 
glycoproteins as well as the number of incorporated terminal sialic-acid 
residues. FSH heterogeneity should be considered as a continuum of 
molecular forms, each with distinct physiochemical characteristics. Heav-
ily sialated (more acidic) FSH has been described to exhibit reduced 
receptor binding and in vitro bioactivity, whereas circulating half-life of 
these forms is extended. In contrast, basic isoforms have been described 
to be more biopotent in vitro (2- to 5-fold), whereas the circulating half-life 
is significantly reduced (Chappel, 1995). Estimates of changes in FSH 
heterogeneity, as assessed by in vitro bioassays, during the menstrual 
cycle are contradictory (Jia et a/., 1986; Padmanabhan et a/., 1988; Reddi 
et a/., 1990) and appear to be dependent on the assay system used. It 
has been speculated that ovarian follicles are recruited in the early follicular 
phase (when gonadal feedback is low) predominantly by more acidic FSH 
isoforms, whereas follicle selection and rupture later during the follicular 
phase is dependent chiefly on more basic FSH isoforms. However, the 
effect of a predominance of more bioactive but shortened half-life forms 
on the overall in vivo biopotency is unknown at this stage, and therefore 
the physiological significance of described changes in FSH isoforms 
remains open for speculation (Fauser et a/., 1997a; Fauser et a/., 1997b). 
1.4 INTRA-OVARIAN MODIFICATION OF FSH ACTION: 
THE AUTOCRINE I PARACRINE CONCEPT 
Besides systemic regulation of FSH action mediated by the hypothalamo-
-pituitary axis, local intraovarian regulation of FSH action also takes place. 
Differences in distribution of various FSH isoforms may affect FSH-recep-
tor interaction. Moreover, interference with post-receptor signal transduc-
tion by growth-factors may also modulate the FSH signal at the ovarian 
level. 
During the follicular phase the dominant follicle continues to mature 
despite decreased stimulation by lower late follicular phase FSH serum 
concentrations (v Santbrink et a/., 1995a). This observation of decreased 
8 
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dependency of the dominant follicle on FSH stimulation strongly suggests 
that the FSH signal is modified within the ovary, either at the level of FSH 
binding to the receptor or by interference with the post receptor signal 
transduction. In addition, the intrafollicular rise in E2 concentrations of the 
dominant follicle was believed to be responsible for the decreased need 
for stimulation by FSH through autocrine short-loop up-regulation (Hsueh 
et al., 1983). However, it is now clear that follicles can mature fully without 
a concomitant rise in E2 (Schoot et al., 1992a). This observation strongly 
suggests that in fact other (intraovarian) factors drive growth of the 
dominant follicle, and disturbed intraovarian regulation may prove to be 
crucially important for cessation of follicle development in PCOS patients. 
Moreover, a 2.5-fold difference in maximum early follicular phase serum 
FSH concentrations - not correlated with cycle characteristics, or age, 
follicular phase duration or follicle growth (van Santbrink et al., 1995a; 
Schipper et al., 1998a) - observed in a group of young women presenting 
with normal ovarian function suggests distinct differences in intraovarian 
regulation under normal conditions. Support for an autocrine I paracrine 
role of the intra ovarian insulin-like growth factors (IGF) system has been 
observed in a study performed by our group (van Dessel et al., 1996) in 
which the IGF-binding protein profile in follicular fluid did change during 
follicle development in the normal cycle, independent of changes in serum. 
Various factors like the growth factor systems (IGF system, IGF-binding 
protein system, epidermal growth factors, and the inhibinlactivin system) 
have been shown to affect follicle development and FSH action in vitro 
(Figure 3), but conclusive evidence for a distinct role in vivo is still lacking. 
1.5 GONADOTROPIN INDUCTION OF OVULATION 
After primary treatment of normogonadotropic oligo- or anovulatory 
infertility with clomiphene-citrate, 30% of these patients will remain 
anovulatory and only 50% of women will conceive (Gorlitsky et al., 1978; 
Imani et al., 1998). For many years second line therapy for this poorly 
defined patient group is gonadotropin induction of ovulation. Although 
indisputably effective, these compounds carry important risks; chiefly 
ovarian hyperstimulation (Stephenson, 1991; Navot et al., 1992) reported 
in literature to occur between 3%-15% of patients (Fauser et al., 1997a) 
and multiple pregnancies (Derom et al., 1993) reported in literature to 
occur between 4%-28% of patients (Fauser et al., 1997a) associated 
with considerable obstetrical complications (Levene et al., 1992; Callahan 
et al., 1994). In an attempt to reduce complication rates various treatment 
schedules have been developed. Schedules reported initially include single 
dose, intermittent or multiple fixed doses and incremental or decremental 
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Figure 3 Schematic representation of growth factors potentially involved in 
late follicular phase enhancement of FSH action. [Reproduced with permission 
from Fauser, B.C., and van Heusden, A.M. (1997a). Manipulation of human 
ovarian function. Endocr Rev 18, 71-106. 
dose regimens (Taymor et al., 1967; Thompson et al., 1970). At present, 
most frequently used administration schedules are 'step-up' regimens; i.e. 
increasing doses of exogenous gonadotropins are administered through 
daily intramuscular injections until ovarian response is considered to be 
'SUfficient'. In an attempt to diminish complication rates, conventional 
step-up regimens were modified to 'low dose, step-up' regimens (Seibel 
et al., 1984; Buvat et al., 1 989; Hamilton-Fairley et al., 1991) starting 
with a lower initial dose (y, or 1 ampule per day) and with small subsequent 
increments (y, ampule) at weekly intervals in case of absent response. 
With the use of low-dose regimens improved clinical outcome has been 
reported. There were lower chances of ovarian hyperstimulation, but in 
some studies at the cost of reduced pregnancy rates (Hull, 1991) and an 
extended period of stimulation. 
The half-life of exogenous urinary FSH in females has been reported to 
be approximately 44 hours (Diczfalusy et al., 1988; Mannaerts et al., 
1993), and if equal daily doses are administered, steady state serum FSH 
concentrations are reached after 5 to 7 days (Mizunuma et al., 1990; 
Schoot et al., 1994). It should therefore be considered that during step-up 
regimens elevated serum FSH concentrations may occur during the late 
follicular phase which may interfere with selection of a single dominant 
follicle (Fauser et al., 1993b; Fauser, 1994; van der Meer et al., 1994). It 
has been shown that the magnitude of FSH accumulation determines 
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ovarian (hyper) response (Ben Rafael et al., 1986). In contrast, the 
dominant follicle shows a decreased dependency of FSH in the normal 
menstrual cycle (Messinis et al., 1990; Hall et al., 1991). Moreover, 
reduced FSH concentrations during the late follicular phase were found to 
be essential for monofollicular development in the monkey model (Zeleznik 
et al., 1985). Low-dose step-up regimens ignore the concept that the 
FSH-threshold should be surpassed for a limited period of time only (a 
narrow 'window') sufficient to allow just one single follicle to be selected 
to gain dominance (Brown, 1978; Fauser et al., 1997a). Since complica-
tions during gonadotropin induction of ovulation, such as ovarian hyper-
stimulation and multiple pregnancy, are related to multiple follicle 
development (Blankstein et al., 1987), it may be worthwhile to focus more 
on various dose regimens and resulting patterns in FSH serum concentra-
tions. In some ovulation induction studies (Dale et a/., 1993) late follicular 
steady-state FSH concentrations were observed during low-dose step-up 
regimens. However, preliminary data suggest that decreasing serum FSH 
concentrations may occur due to negative estrogen feedback action in 
some patients (White et a/., 1995) or using intravenous low-dose step-up 
FSH administration (van der Meer et a/., 1996). 
Our group has focused on a way to establish serum FSH concentrations 
that mimic physiology more closely during gonadotropin induction of 
ovulation (Fauser, 1994). To accomplish this, a decreasing - 'step-down' 
- dose regimen has been developed. Initially, a starting dose of 3 ampulesl 
day was administered in patients pretreated with GnRH-agonists. Patients 
were randomized for 2 different dose regimens: (1) a single fixed step-
down of 1 ampule/day on day 3 followed by a fixed dose of 2 ampuleslday 
until ovulation, or (2) a single fixed step-down of 1 ampule/day on day 3 
followed by a second step-down to a daily dose of 1 ampule/day on the 
first day a follicle > 9 mm was recognized sonographically. This treatment 
regimen still resulted in considerable ovarian hyper-response especially 
concerning medium-sized follicles and high pre-ovulatory estrogen con-
centrations (Schoot et a/., 1992b). Modification to a low-dose step-down 
regimen (Schoot et al., 1995) with a starting dose of 2 ampuleslday and 
each step-down by Y, ampule/day resulted in a 2.1-fold increase of serum 
FSH followed by a subsequent decrease of 10% per day during 4 days, 
remarkably similar to previous studies in the monkey model (Zeleznik et 
al., 1986). These early studies have provided evidence that, indeed, a 
step-down dose regimen closely resembles late follicular phase serum FSH 
concentrations of the spontaneous cycle (Schoot et a/., 1994; van Dessel 
et a/., 1995) and can be applied in clinical practice as a safe and effective 
treatment alternative (van Santbrink et al., 1995b). The modified step-
down regimen presently used has a fixed starting dose of 2 ampules of 
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gonadotropin per day and from the first day a dominant follicle (a follicle 
210 mm in diameter) is sonographically recognized, the daily gonadotropin 
dose is decreased by Y, ampule. Every 3 days another step down by Y, 
ampule is performed until the minimal daily dose of 1 ampule/day has been 
reached or until hCG can be administered. We have abandoned the use of 
GnRH agonists without any loss of clinical efficacy or safety. 
1.6 OUTLINE OF THE THESIS: STUDIES AND OBJECTIVES 
The study objective of this thesis was, after strictly defining the study 
population, to develop a regimen for induction of ovulation that mimics 
physiology maximally to improve treatment results (monitored by serum 
hormone estimation of FSH and E2 and transvaginal sonography of follicle 
development in the ovaries) compared to the currently used ovulation 
induction regimens. 
The first objective of this study was to review current opinion on 
endocrine and sonographic aspects concerning the normal human men-
strual cycle. The second objective was to confirm and extend knowledge 
of physiological aspects of dynamics in follicle development in the ovary. 
The third objective was on one hand to review the various ways of 
classification of normogonadotropic infertility in literature and transpose 
these different criteria on our own study population using normal endocrine 
and sonographic values derived from a control group, and on the other 
hand to determine whether sonographic parameters had any predictive 
value for endocrine abnormalities used for PCOS. The fourth objective was 
to determine whether endocrine or sonographic PCOS parameters had 
predictive value for ovarian response in ovulation induction. The fifth 
objective was to compare clinical results of step-down induction of 
ovulation using exogenous gonadotropins with results of low-dose step-up 
regimens in literature. The sixth objective was to compare a step-down 
dose regimen for induction of ovulation using exogenous FSH with a 
low-dose step-up regimen in a prospective randomized way. Conclusions 
drawn from the studies described in this thesis are presented in the general 
discussion. 
12 
2 
The normal menstrual cycle 
2.1 GENERAL INTRODUCTION 
To understand pathological conditions involved in arrested follicle matu-
ration and anovulation, in-depth knowledge of physiology of dominant 
follicle selection and dominance is mandatory. As this process is still poorly 
understood, development of sonographic imaging combined with hor-
monal assays have created new perspectives for evaluation of normal 
physiological conditions in which the process of recruitment and selection 
of a dominant follicle in the human ovary takes place. A report on follicular 
development in the normal menstrual cycle monitored by abdominal 
ultrasonography was first published by Hackeloer (Hackeloer et al., 1979). 
Only cystic structures;o,l 0 mm in diameter could be recognized as follicles, 
which resulted in monitoring of a dominant follicle only. A first report on 
transvaginal sonographic monitoring of follicular growth during the normal 
menstrual cycle (Meldrum et al., 1984), indicated a big step forward 
regarding improved resolution. A study from our group (Pache et al., 1990) 
generated reliable reference data for ovarian follicle number and size 
(follicles could be identified from a 2 mm diameter stage), throughout the 
normal menstrual cycle. 
The objective of the present study was to confirm and extend obser-
vations of previous studies from our group, regarding FSH regulation of 
follicle selection and dominance monitored by frequent transvaginal sonog-
raphy and blood sampling. Better understanding of the sequence of events 
could have clinical implications for processes involved in anovulation 
(disturbed follicle growth), induction of ovulation (selection of a dominant 
follicle) and residual ovarian activity during contraceptive medication 
(especially follicle dynamics during the pill-free interval). 
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2.2 DECREMENTAL FOLLlCLE-STIMULA TlNG HORMONE AND 
DOMINANT FOLLICLE DEVELOPMENT IN THE NORMAL 
MENSTRUAL CYCLE 
2.2.1 Introduction 
Although the human ovary has been the subject of numerous studies, many 
details with regard to its function are yet to be elucidated. Cyclic follicular 
changes in the ovary are induced by alterations in the hypothalamo-
pituitary-ovarian axis. During the luteal·follicular transition serum FSH 
concentrations rise (Hall et al., 1992) above the 'threshold' (Brown, 1978) 
for follicle stimulation. Consequently, a cohort of follicles gains gonado-
tropin dependence and continues its development, a process referred to 
as 'recruitment' (Goodman et al., 1983). Decremental FSH concentrations 
during the follicular phase of the cycle appear to be essential for selection 
of a single dominant follicle and atresia of the remaining cohort of follicles 
(Zeleznik et ai, 1985). Although FSH concentrations decline, the dominant 
follicle continues its growth due to enhanced sensitivity for FSH stimula· 
tion presumably caused by upregulation by intra·ovarian factors (Hsueh et 
al., 1986). 
Previous human studies concerning cyclic ovarian function chiefly 
involved morphology (Chikazawa et al., 1986), measurement of follicle 
fluid steroid concentrations (McNatty et al., 1979) or primary granulosa 
cell cultures (Erickson et al., 1979; Hillier et al., 1980). A major step 
towards improved monitoring of the dynamics of follicle development in 
a noninvasive way was the introduction of pelvic sonography (Hackeloer 
et al., 1979). Using the transvaginal route, allowing the use of high 
frequency probes in the close proximity of the ovaries, follicles as small 
as 2 mm in diameter can be quantified (Pache et al., 1990). Until now, 
few sonographic studies have been published in which follicle growth and 
selection in the normal human cycle has been described in detail using 
transvaginal sonography (TVS). Due to major individual variability, the 
correlation between endocrine and sonographic parameters was hampered 
in our previous study of normal volunteers (Pache et al., 1990). The present 
follow-up study in carefully selected women exhibiting normal ovarian 
function was undertaken to investigate the relationship between decreas-
ing FSH concentrations and follicle development (as estimated by TVS and 
changes in serum E2 concentrations). More insight into FSH regulation of 
follicle selection and dominance under normal conditions appears to have 
major clinical relevance and may lead to a better understanding of residual 
ovarian activity during oral contraceptive medication (Fauser et al., 
1993a), of arrested follicle maturation in polycystic ovaries, and of ovarian 
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response following exogenous gonadotropins for induction of ovulation 
(Fauser et al., 1993b). 
2.2.2 Patients and methods 
Subjects and study design: This study was approved by the local Ethics 
Review Committee, and written informed consent was obtained from each 
volunteer. Sixteen regularly cycling women participated in this study. They 
entered this study through poster advertisement and were paid for their 
participation. Median age was 28 years (range, 21-34 years), median 
body mass index (BMI; weight divided by height squared) was 22 kg/m 2 
(range, 19-25 kg/m2 ). All subjects had neither received hormonal treat-
ment for at least 3 months before this study nor had they undergone any 
type of abdominal surgery. Daily blood samples were obtained, starting 
two days before expected menses (based on the length of the previous 
cycle) until the day of ovulation. One more sample was collected at 6 days 
after ovulation. Serial TVS was performed on cycle day 1 or 2, 3 or 4, 5 
or 6, and so on, until there was sonographic evidence of ovulation. 
Sonographic examinations were performed by two observers using a 
5.0 or 7.5 MHz. transvaginal transducer. An individual was always 
scanned by the same observer. The ovaries were localized in relation to 
the iliac vessels. Follicles appeared as echo-free round or ovoid translucent 
structures. The follicle number was established by scanning each ovary 
from the inner to the outer margin in longitudinal cross sections, as 
described previously Wache et al., 1990; Schoot et al., 1992b). Follicle 
size was determined from two (longitudinal and anteroposterior) or three 
(longitudinal, anteroposterior, and transverse) dimensions depending on 
the longitudinal diameter of the follicle « 10mm or ~10mm). In each 
instance the mean of the measurements was taken to be the follicle 
diameter. 
Hormone estimations: Daily blood samples obtained through venepunc-
ture, were centrifuged within two hours after withdrawal. Serum was 
stored at -20°C, until assayed. Serum was assayed for immunoreactive 
LH and FSH, E2 and P. Kits for measurement of LH and FSH by 
immunoradiometric assay (IRMA) were obtained from Medgenix (Fleurus, 
Belgium) as described previously (Fauser et al., 1990). Progesterone was 
estimated by RIA as described previously (de Jong et al., 1974) and 
E2-concentrations were estimated using RIA kits provided by Diagnostic 
Products Corporation (Los Angeles, CAl. Intra-assay and interassay coef-
ficients of variation were < 5% and < 15% for LH, < 3% and < 8% for 
FSH, < 16% and < 17% for P, and < 15% and < 18% for E2, respec-
tively, as described before Wache et al., 1990; Fauser et al., 1990). The 
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applied FSH-IRMA has demonstrated a fairly good correlation with FSH 
bio-activity (as estimated by the in vitro rat granulosa cell aromatase assay) 
under various clinical conditions such as oligospermia (Fauser et al., 1990) 
or anovulation (Fauser et al., 1991). 
Data analysis: Results are presented as the mean ± SO or median and 
range as indicated. Dependent on the particular evaluation, the time-scale 
used was based on: [1] the first menstrual day, [2] the first day of 
sonographic detection of a dominant follicle, or [3] the day of the LH-surge. 
Correlation coefficients given were Pearson's. Comparisons of various 
parameters within subjects were performed using Wilcoxon's test. P 
values given are two-sided, with 0.05 taken as the limit for statistical 
significance. Piece-wise linear regression was used to asses the relation 
between log(E2) and cycle day. With this method, often referred to as the 
'broken stick method' (Neter et al., 1974), an estimation is made of the 
cycle day at which the best fitting linear relation changes to one with a 
greater slope. Based on previous sonographic studies the dominant follicle 
was defined as exceeding a diameter of 9 mm and being at least 2 mm 
larger than the other follicles (Pache et al., 1990). The follicle also has to 
fit optically in the growth curve of the dominant follicle, to exclude 
incidental presumably atretic follicles that also fit the criteria for dominance 
without subsequent growth. 
2.2.3 Results 
Hormones: Median cycle length was 2B days (range, 26 to 31 days) with 
a median follicular phase of 17 days (range, 12 to 20 days) and a luteal 
phase of 12 days (range, 10 to 14 days). Hormone profiles (Table 1) 
confirmed the presence of normal ovulatory cycles in each volunteer with 
a median midluteal plasma P concentration of 18 ng/mL (range, 5 to 
25 ng/mL [conversion factor to SI unit, 3.180]) 6 days after the LH-peak. 
The LH-peak occurred on cycle day 16 (range, cycle day 10-19), the 
median maximal plasma LH concentration was 33 mlU/mL (range, 14 to 
59 mlU/mL [conversion factor to SI unit, 1.000]). The median maximal 
plasma FSH concentration in the early follicular phase was 6.6 mlU/mL 
(range, 4.4 to 11.2 mlU/mL [conversion factor to SI unit, 1.000]) on cycle 
day 5 (range, cycle day 1 to 9). No correlation was found between this 
maximal FSH concentration and (for values see Table 1) magnitude of the 
FSH decrease (r = -0.37; P = 0.17), duration of the follicular phase 
(r = 0.14; P = 0.61) or maximal preovulatory E2 plasma concentration 
(r = -0.05; P = 0.86). The median minimal FSH plasma concentration in 
the late follicular phase (Figure 4) was found on cycle day 13 (range, cycle 
day 8 to 16) and was 2.9 mlU/mL (range 0.7 to 5.7 mIU/mL). The mean 
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Table 1 Endocrine and sonographic follicular phase characteristics of 16 
participating regularly menstruating female volunteers. 
Maximum EFP' FSH cone. (lUlL) 
Minimum LFP' FSH cone. (lUlL) 
Foil. phase FSH decrease (lUlL/day)' 
Dominant follicle: 
first sonographic appearance (CD f) 
follicle size on CD 9 (mm) 
growth rate (mm/day) 
pre·ovulatory size (mm) 
First day of sign. E, rise (CD)' 
Maximum LFP E, cone. (pg/mL)' 
Mid·luteal P (nmoI/L) 
Median 
6.6 
2.9 
0.5 
9 
11 
1.7 
21 
8 
255 
57 
EFP = early follicular phase, LFP = [ate follicular phase. 
*From cycle day 5-13. 
teo = cycle day. 
tConversion factor to 81 unit, 3,671. 
§On day LH + 6 
Range 
4.4-11.2 
0.7-5.7 
0.1-0.9 
5-12 
9-15 
0.9-2.6 
18-30 
4-15 
181-471 
17-78 
FSH-decrease during the period between maximal and minimal levels of 
FSH was linear (P< 0.001) and 0.5 ± 0.05 miU/mL per day (range, 0.1 to 
0.9 mIU/mLlday), and significantly correlated (r = 0.62; P< 0.01; Figure 
5) with the log(E2) slope for the period between selection day and the 
preovulatory E2 peak. Early follicular phase plasma E2 concentrations for 
individual subjects appeared constant or increased slightly up to a certain 
cycle day and increased log-linearly at a higher rate thereafter. The median 
cycle day at which this change occurred, assessed using the broken stick 
method (Figure 6), was day 8 (range, day 4 to 15), 7 days before the 
LH-surge (range, 4 to 9 days), with a plasma E2 concentration of 47 pg/mL 
(range, 25 to 97 pg/mL [conversion factor to SI unit, 3.671 J). The 
pre-ovulatory maximal E2 concentration (255 pg/mL; range, 181 to 
471 pg/mL) Was found on cycle day 15 (range, cycle day 9 to 19). The 
mean E2 doubling time was 2.7 days (range, 1.8 to 3.8 days). The day of 
the maximal serum E2 concentration coincided with the start of the 
LH-surge for each subject. 
Sonography: All volunteers showed normal follicular development 
throughout the follicular phase, with one dominant follicle that ovulated. 
No significant differences were found in the distribution of the mean follicle 
sizes between both ovaries on cycle day one. In the early follicular phase 
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Figure 4 Box and whisker plots representing serum FSH (upper panel) and E2 
(lower panel) concentrations in 16 regularly menstruating female volunteers, 
synchronized around the initiation of menses, around the first day of visualiza-
tion of the dominant follicle (dominance) using TVS, and preceding the serum 
LH peak (conversion factor to 81 unit for E2, 3.671). Boxes encompass values 
between the 25th and 75th percentile, horizontal lines represent median values, 
and whiskers give the 95% range of the values. 
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Figure 5 Correlation between the individual daily decrease in serum FSH levels 
versus the E2 doubling time between cycle day 5 and 15 in 16 regularly cycling 
female volunteers Ir ~ 0.6; P ~ 0.01). 
the mean rate of follicular growth was 0.31 mm/day in the dominant ovary 
and 0.14 mm/day in the nondominant ovary. For the late follicular phase 
these slopes were -0.21 and -0.12 mm/day, respectively (data not 
shown). No significant difference between growth rates of nondominant 
follicles in the dominant and nondominant ovary in the early or late follicular 
phase was detected (P ~ 0.22 and P = 0.20, respectively). For both ovaries 
the mean growth slopes were significantly greater than zero (P< 0.02) in 
the early follicular phase and significantly less than zero (P< 0.02) in the 
late follicular phase. The first day the dominant follicle was observed by 
ultrasound (US) was cycle day 9 (range, cycle day 5 to 12), 6 days before 
the LH-surge (range, 4 to 10 days), at a diameter of 11 mm (range, 9 to 
15 mm). In the nondominant ovary a follicle exceeded 9 mm in diameter 
and was at least 2 mm larger than the other follicles in 2 individuals. 
Because there was no progression in growth (no 'optically fitting in the 
growth curve'), these follicles were not considered to be dominant. The 
median growth rate of the dominant follicle was 1.7 mm/day (range, 0.9 
to 2.6 mm/day), and appeared to be linear for each patient. Ovulation was 
detected by US on cycle day 17 (range, cycle day 13 to 20). The mean 
preovulatory follicle size was 21 mm (range, 18 to 30 mm). 
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Figure 6 Rise in individual log(E 2) serum concentrations (processed with the 
'broken stick' method; upper panel) and diameter of the dominant follicle (lower 
panel) in 16 regularly cycling female volunteers, synchronized around the first 
day of visualization of the dominant follicle by TVS. The dashed line in the upper 
panel represents one subject in which no change in E2 slope could be 
established, because a dominant follicle was observed the first day of 50nog-
raphic examination. Conversion factor to SI unit for E2• 3.671. 
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Hormones and sonography: At the time of the early follicular FSH peak, 
mean duration of the period until selection of the dominant follicle was 4 
days (range, 0 to 8 days). Early follicular phase maximal FSH concentra-
tions and day of follicle selection, duration of the follicular phase, growth 
slope of follicles, pre-ovulatory follicle size or maximal E2 concentrations 
were not correlated (data not shown). No correlation was found between 
the decrease of FSH plasma concentrations and increase of the diameter 
of the dominant follicle (f = 0.23; P = 0.39). Similarly, no correlation could 
be demonstrated between decrease of FSH concentrations (or duration of 
this decrease) and day of selection of the dominant follicle, duration of the 
follicular phase, preovulatory dominant follicle size or maximal preovula-
tory E2 concentrations (data not shown). The first day of a significant rise 
in E2 plasma concentration correlated strongly with the day at which the 
dominant follicle appeared sonographically (f = 0.84; P<0.001; Figure 6). 
From the day the dominant follicle was first seen by TVS (median cycle 
day 8) until the day of the maximal E2 plasma concentration (median cycle 
day 15), there was a significant correlation between the rate of increase 
in E2 plasma concentrations and dominant follicle growth (f = 0.53; 
P=0.04). 
2.2.4 Discussion 
In this longitudinal study an attempt was made to correlate decremental 
serum FSH concentrations during the follicular phase of the normal menstrual 
cycle with dominant and nondominant follicle development. Frequent TVS 
and measurement of E2 serum concentrations were used to monitor follicle 
development. All cycles in this study appeared ovulatory, with gonadotropin 
and steroid hormone concentrations within the normal range according to 
other studies (Hackeloer et al., 1979; Landgren et al., 1980). 
In the early follicular phase 2.5-fold differences in maximum FSH 
concentrations were observed. Moreover, correlations between maximum 
FSH concentrations and follicular phase characteristics (such as follicular 
phase length or maximum E2 concentrations) were absent suggesting that 
distinct differences in FSH threshold concentrations for ovarian stimulation 
are present even in this carefully selected group of young, healthy, 
normal-weight women exhibiting normal ovarian function. This observa-
tion supports and extends the ovarian 'threshold concept', initially put 
forward by Brown (Brown et al., 1978), suggesting that every woman has 
an individual FSH concentration that should be surpassed for stimulation 
of development of a cohort of follicles. Under normal conditions, the rise 
in FSH takes place during the luteal-follicular transition and is correlated 
closely with the preceding LH peak as opposed to menses (Hall et al., 
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1992). Therefore, it should be preferred to use the previous LH peak rather 
than cycle day (which refers to the initiation of menses) as point of 
reference to characterize regulation of follicle growth. A rise in serum FSH 
and subsequent follicle growth can also be induced artificially by removal 
of the corpus luteum or the dominant follicle (Nilsson et al., 1982), 
indicating that follicles that are ready to be recruited are present throughout 
the cycle. Maximum FSH concentrations of 6.6 mlU/mL (range, 4.4 to 
11.2 mlU/mL) were reached on cycle day 5, followed by a linear decrease 
of 0.5 mlU/mL per day (range, 0.1 to 0.9 mlU/mL per day) until cycle day 
13 (3 days before the LH peak). It appears that the magnitude of decrease 
of endogenous FSH concentrations is independent of initial FSH concen-
trations. During the period between cycle day 5 and 15 the slopes for FSH 
and Ez concentrations showed a significant negative correlation, indicating 
that late follicular phase Ez production (presumably by the dominant 
follicle) may be stimulated to a greater extent in women with a slower 
decrease in FSH. Hence, the magnitude of stimulation of the aromatase 
enzyme (and subsequent estrogen biosynthesis) by the dominant follicle 
is related closely to the extent of FSH stimulation. The dominant follicle 
becomes less dependent on FSH stimulation, allowing continuation of its 
development in the late follicular phase, whereas remaining follicles of the 
same cohort undergo atresia due to insufficient stimulation by FSH. The 
association between FSH and Ez concentrations was studied previously 
in the monkey model, which led the authors to conclude that FSH secretion 
is suppressed by Ez to accomplish selection of a single dominant follicle. 
Indeed, interference with decremental FSH concentrations (using Ez 
antibodies) resulted in multiple follicle development (Zeleznik et al., 1985). 
Increasing concentrations of inhibin during the follicular phase also have 
been shown to inhibit pituitary FSH release (8urger, 1993). 
Aromatase activity was found to be present in granulosa cells obtained 
from follicles beyond 6 to 8 mm in diameter (Erickson et al., 1979; Hillier 
et al., 1980), and a close correlation between follicle fluid Ez concentra-
tions and follicle diameter has been established (McNally et al., 1979). In 
our study a clear rise in plasma Ez was seen from cycle day 8 onwards 
(coinciding with the sonographic visualization of a dominant follicle at a 
size of > 9 mm). This indicates that the induction of aromatase activity in 
the follicle destined to gain dominance does not contribute to serum Ez 
concentrations before the follicle can be discerned as the dominant one. 
The observation that endocrine and sonographic indications of dominant 
follicle selection exhibit a close resemblance, strongly indicate that visu-
alization of the dominant follicle by TVS represents a relevant biological 
phenomenon. Our sonographic data on the development of the dominant 
follicle match quite well with previous studies. A linear growth rate of 
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1.7 mmlday was found for the dominant follicle with a median preovula-
tory follicle size of 21 mm (Hackeloer et al., 1979; Pache et al., 1990; 
Eissa et al., 1986). There is some controversy with regard to a correlation 
between dominant follicle diameter and serum E2 concentrations in 
previous studies using abdominal sonography (Lenz, 1985). Using mor-
phology, however, a clear correlation has been established (Chikazawa et 
al., 1986). In the present study a significant correlation between increase 
of serum E2 concentrations and dominant follicle growth was found in 
support of the notion (Hackeloer et al., 1979; Baird et al., 1975) that 
circulating E2 is produced mainly by the dominant follicle. The absence of 
a correlation between decreasing FSH and follicle size indicates that 
growth of the dominant follicle may be dependent on other (intraovarian) 
factors next to FSH. 
In conclusion, the present study in female volunteers with normal 
menstrual cycles indicates that a major difference in FSH threshold 
concentrations for stimulation of follicle development does exist. It was 
confirmed that the dominant follicle exhibits enhanced sensitivity for FSH 
and the magnitude of follicular phase decrease in FSH affects dominant 
follicle E2 production. In addition, appearance of the dominant follicle on 
US is related closely to a distinct rise in serum E2 concentrations. These 
notions may have major clinical implications for various conditions such 
as induction of ovulation using exogenous gonadotropins or residual 
ovarian activity during steroid contraceptive medication. Interestingly, 
enhanced sensitivity of the dominant follicle for FSH has been demon-
strated also in clomiphene-citrate resistant anovulatory pcas patients 
during exogenous gonadotropins administered in decremental doses 
(Schoot et al., 1993). The resemblance with the pattern of endogenous 
FSH concentrations reported here is striking, which emphasizes the need 
for a further evaluation of the concept of elevated FSH threshold in pcas 
patients. Moreover, at the end of the seven-day pill-free interval during 
oral contraceptive medication, serum FSH concentrations are in the same 
order of magnitude as during the early follicular phase of normal cycles. 
It therefore seems reasonable to assume that follicle recruitment already 
has been initiated before contraceptive medication of the next month is 
started. Indeed, ovarian follicles exceeding 10 mm in diameter have been 
observed in approximately 30% of women using oral contraceptives (for 
review see Fauser et al., 1993b). Apparently, follicle maturation is arrested 
at a stage just before dominant follicle selection (and the diminished need 
for FSH). Altogether, data presented in this study may serve as a reference 
for better understanding of the above mentioned conditions, and may elicit 
further studies with regard to mechanisms regulating normal and abnormal 
follicle development in the human. 
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Polycystic ovary syndrome 
3.1 GENERAL INTRODUCTION 
peos is a poorly understood and poorly defined heterogeneous entity. 
The fact that several etiological factors lead to a common endpoint of 
polycystic changes in the ovary, may contribute to confusion. Parameters 
used for peos diagnosis in patients presenting with anovulatory infertility 
include elevated serum LH concentrations, hyperandrogenemia, or poly-
cystic ovaries on ultrasound. The fact that diagnostic criteria used in the 
literature are not identical may have added to confusion and have 
weakened the development of effective and safe therapeutic options. This 
is of importance, since treatment of infertility associated with peos may 
be difficult, and response to medication is accompanied by high rates of 
hyperstimulation and early pregnancy loss (Regan et al., 1990). 
In the following study we have attempted to evaluate various patient 
characteristics used in the literature for peos diagnosis: first we set strict 
normal cut-off levels for these criteria in a control population and trans-
posed these to the abnormal population using anovulatory normogonado-
tropic infertility as inclusion criterion. In a second preliminary study we 
compared various patient characteristics as markers of disease and tried 
to validate their usefulness as a predictor of treatment response in 
ovulation induction using exogenous gonadotropins. 
3.2 CLASSIFICA TlON OF NORMOGONADOTROPIC 
ANOVULA TORY INFERTILITY: POL YCYSTIC OVARIES 
DIAGNOSED BY ULTRASOUND VERSUS ENDOCRINE 
CHARACTERISTICS OF POL YCYSTIC OVARY SYNDROME 
3.2.1 Introduction 
Polycystic ovary syndrome (PCOS) represents a heterogeneous group of 
patients with a variety of underlying abnormalities. Moreover, the lack of 
uniformity in criteria used for peos diagnosis further adds to confusion 
surrounding this syndrome. Initially, it was reported by Stein and Leventhal 
that morphology diagnosis of polycystic ovaries was associated with a 
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specific medical history and characteristic findings upon physical exami-
nation (infertility, oligo/amenorrhea and masculinization). More recently, 
diagnosis of PCOS was based on clinical symptoms and biochemical 
parameters. At present, some investigators apply just a single biochemical 
marker such as elevated serum LH concentrations (Scheele et al., 1993) 
or high androgen concentrations (Lobo, 1985) to define PCOS, whereas 
others use a combination of these two parameters (Ardaens et al., 1991). 
As pelvic ultrasound (US) was introduced in the early 1980s, this new 
and noninvasive technique allowed morphological assessment of the 
ovaries on a wide scale. Sonographic appearance of polycystic ovaries 
became an important criterion for PCOS diagnosis (Adams et al., 1985; 
Balen et al., 1995; Fox et al., 1991). In fact, many investigators now use 
US as the sole criterion for diagnosis of this syndrome (Balen et a/., 1995; 
Fox et al., 1991; Takahashi et al., 1993). Sonographically diagnosed 
polycystic ovaries can be enlarged (Puzigaca et al., 1991; Pache et al., 
1993), contain an increased number of follicles (Adams et al., 1985; 
Obhrai et a/., 1990), or exhibit an increased amount or density of stroma 
(Adams et al., 1985; Dewailly et a/., 1994). These characteristics are 
sometimes used as a single parameter or are combined (Adams et al., 
1985; Balen et al., 1995, Dewailly et al., 1994). At present, transvaginal 
sonography (TVS) with enhanced resolution is most commonly used for 
US evaluation of ovaries. However, criteria determined by transabdominal 
US (Adams et al., 1 985) are still used frequently (Balen et al., 1995; Obhrai 
et al., 1990; Robinson et al., 1992). 
Over 10 years after the introduction of pelvic US, still no agreement 
has been reached on criteria used for polycystic ovary diagnosis nor on 
its validity. It is unclear to what extent the presence of polycystic ovaries 
overlaps with other endocrine criteria used to diagnose PCOS such as 
elevated LH or androgen concentrations. It appears essential to evaluate 
various criteria for PCOS diagnosis to create a stronger basis for further 
uniform evaluation of this entity. 
3.2.2 Patients and methods 
This study was approved by the local Ethics Review Committee and 
informed consent was obtained from all participants. Forty-eight control 
subjects were selected by poster advertisement and paid for participation. 
Inclusion criteria were regular menstrual cycle (26 to 30 days), age 
between 20 and 35 years, normal weight (body mass index [BMI; weight 
divided by height squared] : 18-26 kg/m 2), and no hormone therapy for 
the last 3 months. On cycle day 3, 4 or 5, TVS was performed and a blood 
sample was taken. For sonographic imaging, we used a 6.5 MHz trans-
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vaginal transducer (Model EUB-415; Hitachi Medical Corporation, Tokyo, 
Japan). The ovaries were localized in relation to the iliac vessels. Follicles 
appeared as round or ovoid translucent structures. The follicle number was 
established by scanning each ovary from the inner to the outer margin in 
longitudinal cross-sections Wache et al., 1991). The ovarian volume was 
estimated according to the following formula: JI,(AxBxC), where A is the 
longitudinal diameter, B the anteroposterior diameter, and C the transverse 
diameter of the ovary (Sample et al., 1977). Mean follicle number and 
mean ovarian volume were calculated as the addition of left and right 
divided by two. Ovarian stroma echogenicity was scored as 1 (normal),2 
(moderately increased) or 3 (markedly increased) as described by Pache 
Wache et al., 1991). Total stroma count was the stroma score addition 
of the left and the right ovary. 
Three hundred and fifty patients attending our Fertility Clinic between 
1991 and 1994 with [1 J infertility, [2J oligomenorrhea (interval between 
periods> 35 days) or amenorrhea (absence of vaginal bleeding for at least 
6 months], and [3J serum FSH concentrations within normal limits (1 to 
10 mlU/mL [conversion factor to SI unit, 1.000J; van Santbrink et al., 
1995a) were included in this study. TVS and blood withdrawal were 
performed at random. PRL concentrations were not used as an exclusion 
criterion because hyperprolactinemia has been described both in hypogo-
nadotropic as well as in peos patients. Timing of sampling may in some 
cases affect the magnitude of serum LH concentrations (due to presence 
of previous exposure to negative feedback action of high P concentrations 
or due to midcycle surge LH concentrations in oligomenorrheic ovulatory 
patients). All patients with periovulatory Ez concentrations (Ez 
> 109 pg/mL [conversion factor to SI unit, 3.671]) or luteal P concentra-
tions (P > 4.7 ng/mL [conversion factor to SI unit, 3.180) were excluded 
(n = 8 and n = 12, respectively). This resulted in a total study population 
of 330 patients. 
Hormone estimations: Blood samples were obtained through venepunc-
ture and centrifuged within two hours after withdrawal. Serum was stored 
at -20°C and assayed for FSH and LH by immunoradiometric assay (IRMA) 
kits provided by Medgenix (Fleurus, Belgium), and AD and T by radioim-
munoassay (RIA) kits provided by Diagnostic Products Corporation (Los 
Angeles, CAl, as described previously (Fauser et al., 1991). Intra-assay 
and interassay coefficients of variation were less than 3% and 8% for 
FSH, less than 5% and 15% for LH, less than 8% and 11 % for AD and 
less than 3% and 5% for T, respectively. 
Data analysis: Results are presented as the mean ± SO if normally distrib-
uted, or median and range if distributed otherwise. Normal distribution of 
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sonographic parameters was tested with the Kolmogorov-Smirnov good-
ness of fit test. Normal range was computed according to a p5 to p95 
confidence interval according to mean ± 1.645 x SD if normally distributed 
(mean ovarian volume, mean follicle number and LH concentration), or it 
was antilogged before calculation if parameters were not normally 
distributed (AD and T concentrations). We compared groups using the 
Mann-Whitney and Wilcoxon rank-sum test and the Chi-square analysis 
of contingency table. 
Used criteria for pcas diagnosis included [1 J elevated LH concentra-
tions, [2J elevated serum androgen concentrations (increased AD and/or 
T concentrations), and [3J polycystic ovaries on TVS (defined as increased 
mean ovarian volume and/or mean follicle number). The upper limit of 
normal for sonographic and endocrine parameters was defined based on 
the 95th percentile of observations in the control population. 
3.2.3 Results 
Control subjects (n = 48) were used to determine the normal range for 
sonographic and endocrine parameters. Median age was 27 years (range, 
21 to 35 years), cycle length was 28 days (range, 27 to 30 days) and BMI 
was 22 kg/m2 (range, 18 to 26 kg/m2). Follicle number per ovary and 
ovarian volume were distributed normally. Mean number of follicles per 
ovary was 7.0 ± 1.7 (upper limit: 9 follicles), mean ovarian volume was 
6.8 ± 2.4mL (upper limit: 10.7 mL), and total stroma count for both 
ovaries never exceeded 3 (Figure 7). Mean LH serum concentration was 
4.1 ± 1.8 mlU/mL (upper limit 6.9 miU/mL, conversion factor to SI unit, 
1.0), median AD concentration was 2.48 ng/mL (range, 1.14 to 
5.29 ng/mL, upper limit 4.41 ng/mL; conversion factor to SI unit, 3.671) 
and median T concentration was 0.58 ng/dL (range, 0.29 to 1.12 ng/dL, 
upper limit 0.89 ng/dL; conversion factor to SI unit 3.467). 
The study population of 330 normogonadotropic oligomenorrheic or 
amenorrheic women with infertility had a median age of 28 years (range, 
17 to 41 years), BMI was 25 kg/m 2 (range, 18 to 55 kg/m2) and median 
duration of infertility was 2 years (range, 1 to 13 years). Serum prolactin 
concentrations were elevated in 28 subjects (8%), in this subgroup correla-
tions between US and endocrine parameters were not different from the 
overall population (data not shown). Age, BMI and duration of infertility were 
distributed equally in both groups (data not shown). Distribution of all 
sonographic criteria (increased follicle number, ovarian volume, and stroma 
count based on the upper limit of normal defined in control subjects) involved 
in polycystic ovary diagnosis in the total study group are depicted in Figure 
8 (top). Increased ovarian volume (41 % of total group) showed 90% overlap 
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Figure 8 Distribution of sonographic characteristics (increased mean number 
of follicles 1;'10 per ovary!. increased mean ovarian volume 1;'10.8 mL) and 
increased total stroma count for both ovaries 1>3) lupper panel), and pees 
diagnostic criteria {elevated androgens [AD :2:4.44 ng/mL {conversion factor to 
SI unit, 3.671} and/or T ;'0.92 ng/dL (conversion factor to 81 unit, 3A67)!, 
elevated LH ILH ;'7.0mIU/mL, Iconversion factor to SI unit, 1.0)) and polycystic 
ovaries [mean ovarian volume ~1 0.8 mL and/or mean number of follicles per 
ovary 21 0) (lower panel) in 330 normogonadotropic oligomenorrhoea or amenor-
rheic infertile patients. Numbers given are percentages of the overall study 
group. The hatched area in both figures represent an identical patient group, 
characterized by polycystic ovaries. 
with increased follicle number (58% of total group) and/or increased total 
stroma count (45 % of total group). For increased follicle number or increased 
total stroma count, overlap with both remaining US parameters was 74% 
and 78%, respectively. In the total study population, 217 (66%) patients 
showed polycystic ovaries on sonographic examination (arbitrarily defined 
as mean ovarian volume ;'10.8 mL and/or mean follicle number per ovary 
;'10). One hundred and twenty (36%) patients exhibited elevated serum 
androgens (AD ;,4.44 ng/mL and/or T;'0.92 ng/dL), and 155 (47%) patients 
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showed increased serum LH concentrations (LH <: 7.0 mIU/mL). Sonographic 
andlor endocrine criteria were not increased in 62 (19%) patients of the 
study group. Three groups with abnormal endocrine or sonographic parame· 
ters had extensive overlap as can be seen in a Venn·diagram showing the 
distribution of percentages of patients in the various groups (Figure 8, 
bottom). Sixty-eight (21 %) patients presented with elevated free-androgen 
index (FAI: T x 1001 sex-hormone binding globulin ratio >9.1 ). Correlations 
with US parameters were not different from T (data not shown). 
In the total study population 252 (76%) patients were oligomenorrheic 
and 78 (24%) patients were amenorrheic. Amenorrheic patients had 
significantly higher serum T concentrations (P = 0.02), mean follicle 
number (P = 0.04), and total stroma count (P<0.001) (data not shown). 
Luteinizing hormone serum concentrations of oligomenorrheic and 
amenorrheic patients were not significantly different (data not shown). 
There was no major difference when Venn-diagrams were plotted for 
oligomenorrheic and amenorrheic patients separately (data not shown). 
Sensitivity and specificity of various sonographic parameters (mean 
follicle number per whole ovary, mean ovarian volume and total stroma 
count) was calculated for elevated T, AD, and LH concentrations (Table 2). 
The best sonographic test for prediction of hyperandrogenicity was 
increased mean ovarian volume, with a sensitivity of 57% and a specificity 
of 67%, The addition of increased stroma score to mean ovarian volume 
and follicle number did not increase the predictive value of the tests (data 
not shown). Receiver operating characteristics (ROC) curves of polycystic 
ovaries (increased ovarian volume andlor follicle number) as a test 
parameter and endocrine pcas criteria (elevated LH or T concentrations) 
showed limited predictive value of sonography for abnormal endocrine 
pcas criteria (Figure 9), The best correlations were between [1] ovarian 
volume and AD (r=0,36; P<0.001) or T (r=0,35; P<0,001) serum 
concentration, and [2] follicle number and T (r = 0.33; P<0.001) or LH 
(r = 0.30; P< 0.001) concentration (data not shown). 
3,2,4 Discussion 
A lack of consensus on criteria used for pcas diagnosis is recognized 
widely (Dunaif et al., 1992). Often accurate information regarding the used 
definition of pcas is insufficiently provided in the literature, Moreover, 
the population from which pcas patients is obtained is poorly charac-
terized. This may cause discrepant observations in different groups of 
patients - all termed pcas - regarding prevalence of this syndrome, 
abnormalities present, and treatment outcome. Correlations between 
sonographic (ovarian volume, follicle number and stroma count) and 
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Table 2 Sensitivity, specificity, predictive value and significance of single and multiple sonographic criteria for polycystic ovary 
diagnosis versus single and multiple endocrine characteristics of peas. 
Test parameter Reference test Sensitivity Specificity PPV NPV Total P' 
Increased ovarian volume High androgen levels t 57 67 49 74 64 <0.001 
(;'10.8 mil High LH levels' 50 67 58 59 59 0.002 
High LH & androgens 61 65 35 84 64 <0.001 
Increased follicle number High androgen levels 70 47 42 73 55 0.03 
(;'10 folliclesl High LH levels 70 50 56 65 60 <0.001 
High LH & androgens 76 46 30 87 53 0.001 
Increased stroma score High androgen levels 52 57 40 68 55 NS 
(;'4) High LH levels 54 60 56 58 57 0.015 
High LH & androgens 53 56 27 79 55 NS 
Increased ovarian volume High androgen levels 77 41 43 76 54 0.001 
and/or follicle number High LH levels 77 45 56 68 60 <0.001 
High LH & androgens 84 40 30 89 50 <0.001 
Increased ovarian volume High androgen levels 49 73 50 72 65 <0.001 
and follicle number High LH levels 42 73 59 58 58 0.005 
High LH & androgens 53 71 35 83 67 <0.001 
PPV "" positive predictive value. 
NPV = negative predictive value. 
Total = percentage correctly idenflfled (positive and negative) of total group. 
*Chi-square test for the association between test-parameter and reference test, 
tHigh androgen levels = A M.44ng/mL (conversion factor to SI unit, 3.671) and/or T '<:!92 ng/dL (conversion factor to SI unit, 3.467). 
~High LH levels = LH '<:!7.0 mlU/mL (conversion factor to SI unit, 1,0). 
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Figure 9 Receiver Operating Characteristics (ROC) curves of mean ovarian 
volume for elevated LH levels (~7.0mIU/mL, conversion factor to SI unit, 1.0) 
(A) and elevated T levels kO.92 ng/dL [conversion factor to SI unit, 3.467]) (B) 
in a group of 330 normogonadotropic oligomenorrhoea or amenorrheic infertile 
patients. The diagonal line represents an imaginary test which has no discrimi-
native power. 
endocrine (LH, AD, and T serum concentrations) characteristics in PCOS 
patients have been described by various authors. For instance, increased 
serum LH and androgen concentrations were demonstrated to be related 
to ovarian enlargement (Balen et al., 1995; Robinson et al., 1992). In a 
group with bilateral polycystic ovaries, on US it was shown that, in patients 
with a more PCO-like sonographic image (more follicles per ovary), 
biochemical disturbances were more apparent (Takahashi et al., 1993). 
Correlation between serum LH concentrations, androgen concentrations, 
and sonographic parameters was also observed in normogonadotropic 
anovulatory infertility (Pache et al., 1993), which is confirmed in the 
present study (data not shown). The predictive value of sonographic 
characteristics for endocrine abnormalities frequently associated with 
PCOS (elevated LH, AD or T concentrations) is hard to find in the literature. 
Fox and colleagues (Fox et al., 1991) studied a group of 65 oligomenor-
rheic or amenorrheic women and suggested that LH and FAI were good 
predictors for polycystic ovaries, although LH and T concentrations as 
single markers had a specificity of both 60% and a negative predictive 
value of 46% and 49%, respectively. We found comparable sensitivity 
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and specificity of sonographic parameters (polycystic ovaries) for the 
prediction of endocrine abnormalities (see Table 2). 
In the present study normal values for sonographic and endocrine 
parameters used for peos diagnosis were defined in a well·characterized 
control population of volunteers (n = 48). These women had strict regular 
cycles, normal weight, and were aged between 20 and 35 years. peos 
diagnostic criteria (increased follicle number and ovarian volume, elevated 
serum T and AD and elevated serum LH) were defined as the 95th 
percentile of the control population. The prevalence of polycystic ovaries 
in this population was 8%. Several other studies (Polson et al., 1988; 
Farquhar et al., 1994) showed that polycystic ovaries can be observed in 
approximately 22% of 'normal' randomly selected women. Differences in 
inclusion criteria for the control population ('women not seeking medical 
treatment' [polson et al., 1988] versus rigid criteria used in the present 
study) and different criteria to define polycystic ovaries easily can explain 
these seemingly discrepant observations. We chose increased mean 
ovarian volume andlor increased mean number of follicles per whole ovary 
as criteria for polycystic ovaries. The first criterion was chosen because: 
TVS has been described to be an accurate and objective way to measure 
ovarian volume (EI Tabbakh et al., 1986), and mean ovarian volume 
exhibits 90% overlap with the remaining 2 sonographic criteria. Mean 
follicle number and total stroma count show only 74% and 78% overlap 
(Figure 8, top). Mean follicle number was chosen as criterion next to mean 
ovarian volume because it increases the sensitivity as compared with 
volume alone (Table 2). Additionally, follicle number is the most frequently 
used and investigated sonographic parameter since its introduction as 
diagnostic criterion for polycystic ovaries by Adams et al. (Adams et al., 
1 985). The value of stroma density in peos diagnosis has been questioned 
in recent studies, because it appears to be a subjective parameter (Ardaens 
et al., 1991; Dewailly et al., 1994). The value of so no graphic parameters 
as a screening test to predict endocrine abnormalities characteristic for 
peos appears to be limited in the present study. Because a good screening 
test must have high sensitivity (i.e., percentage of the test indicates 
presence of the disease of the total disease group) rather than specificity, 
mean follicle number as a single test and mean follicle number andlor 
ovarian volume as a combined test appear the most favorable (Table 2). 
Although the combined sonographic test has the highest sensitivity, the 
ROe curves (Figure 9) show that the AUe for the prediction of both 
elevated T or LH concentrations did not exceed 0.65 and therefore may 
be categorized as a test with limited discriminative power. 
Only normogonadotropic (WHO class II [World Health Organization, 
1993]) oligomenorrheic or amenorrheic infertile patients were included in 
34 
POLYCYSTIC OVARY SYNDROME 
this study. We chose this particular classification based on serum FSH 
concentrations within normal limits, because peas has been described as 
part of this group. Subdivision of these patients according to criteria used 
to identify peas (Fig 8, bottom) showed much overlap in the 3 groups of 
polycystic ovaries, elevated LH concentrations, and hyperandrogenemia, 
whereas 19% of subjects did not fit any criterion. In addition, only 20% 
of patients fulfilled all criteria. Recent studies claim that US has a tendency 
to overestimate peas (Abdal Gadir et al., 1992). This is in line with the 
present results indicating that 21 % of patients present with polycystic 
ovaries without endocrine signs of peas. Elevated serum LH concentra-
tion and slightly decreased FSH concentration are well-established criteria 
for peas diagnosis. This also can be expressed as the LH:FSH ratio. 
Although this ratio has been used as an important diagnostic criterion in 
some studies (Scheele et al., 1993; Fox et al., 1991), recent literature 
shows reduced emphasis on measurements of serum gonadotropin con-
centrations for peas diagnosis (abhrai et al., 1990; Lobo et al., 1983). 
Pulsatile release of LH as well as timing of blood withdrawal and assay 
variability (RIA vs. IRMA) makes it questionable to use this parameter as 
the sole diagnostic criterion (Robinson et al., 1992; Fauser et al., 1992). 
In our study, 85% of patients presenting with elevated serum LH 
concentrations suffered from polycystic ovaries andlor elevated serum 
androgens. 
Hyperandrogenicity is perceived as the most important biochemical 
parameter for peas diagnosis (Dunaif et al., 1992). Steroid hormones of 
adrenal or ovarian origin (T, AD, and dehydroepiandrosterone sulfate 
[DHEAS]) are frequently elevated in peas patients. Dehydroepiandros-
terone sulfate is a marker for adrenal hyperandrogenism (Rittmaster et al., 
1994), but generally is excluded as a peas diagnostic criterion. Most 
authors agree that T and AD are the best parameters for detection of 
hyperandrogenism (Fox et al., 1991; Pac he et al., 1993; Robinson et al., 
1992). In practice, hyperandrogenicity is defined most frequently as 
elevated serum AD andlor T concentrations. Androstenedione concentra-
tion and ovarian enlargement have been reported to be correlated in peas 
(Balen et al., 1995; Puzigaca et al., 1991), which is confirmed in the 
present study (r = 0.36; P< 0.001). However, the most sensitive single 
androgen for discrimination of peas is reported to be T (Pac he et al., 
1993; Robinson et al., 1992), which equals present results. Serum 
androgen concentration may be the most valuable marker for peas, 
because this is correlated best to both sonographic observations and 
elevated LH concentrations. 
We conclude that - after defining in a control population strict cutoff 
levels for sonographic and endocrine peas diagnostic criteria - consider-
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able overlap between these parameters was found in normogonadotropic 
oligomenorrheic or amenorrheic infertile women. However, the predictive 
value of polycystic ovaries (on US) for endocrine abnormalities was limited. 
This cross-sectional study should be followed by a longitudinal follow-up 
study to investigate which of these initial screening parameters are best 
predictors for success or complication rates during induction of ovulation. 
3.3 PREDICTORS OF FOLLICLE DEVELOPMENT IN 
GONADOTROPIN INDUCTION OF OVULATION USING A 
DECREMENTAL DOSE REGIMEN 
3.3.1 Introduction 
Although an extensive number of classifications for anovulatory infertile 
patients have been proposed over the years, non of these - mostly 
descriptive - classifications seem to correlate with treatment outcome 
following gonadotropin induction of ovulation. Patient characteristics like 
age, obesity, and duration of infertility for example are known for their 
influence on treatment outcome (Dar et al., 1980; McCluer et al., 1992). 
Recently it has been reported that parameters can be identified in infertile 
couples that predict chances for spontaneous conception and attempts 
are made to combine these as a predictive model for overall chances of 
conception (Eimers et al., 1994; Collins et al., 1995). In addition, it should 
certainly be helpful if treatment response following ovulation induction 
could be predicted in anovulatory patients. It is generally stated that 
polycystic ovary syndrome (PCOS) patients are at risk of low success rates 
when treated with clomiphene-citrate for induction of ovulation. Therefore 
the majority of PCOS patients need exogenous gonadotropins as a 
second-line therapy. Could it be possible to divide the overall group into 
gonadotropin 'good-responders' and 'bad-responders' based on initial 
screening? In the literature there is a lack of uniformity in defining 
subgroups in narmogonadotropic oligo- or amenorrheic infertility (WHO II; 
van Santbrink et al., 1997a). Of the various criteria used to describe this 
subgroup, apart from clinical symptoms, the most frequently reported are 
serum LH, serum androgens (elevated AD andlor T) and sonographic 
criteria for polycystic ovaries (ovarian volume and follicle number). 
The objective of the present study is to evaluate criteria which have 
been used previously by our group for classification (clinical, endocrine, 
and sonographic characteristics), and to try to validate their usefulness as 
a predictor of treatment response in a group of infertile patients with 
normogonadotropic clomiphene-resistant oligo- or amenorrhea treated 
with exogenous gonadotropins. 
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3.3.2 Patients and methods 
Patients: One hundred and eight patients presenting with infertility, 
oligomenorrhea (interval between periods <:35 days) or amenorrhea 
(absence of vaginal bleeding <:6 months) and serum FSH concentrations 
within normal limits (1 -10 IU/L) were included in this study. All participants 
suffered from clomiphene-resistant anovulation (CRA, failure to ovulate 
despite increasing dose of clomiphene-citrate, with doses up to 150 
mg/day from cycle day 3 to 7 during at least 3 consecutive cycles) or 
clomiphene-failure (defined as failure to conceive despite increasing dose 
of clomiphene-citrate, with doses up to 150 mg/day from cycle day 3 to 
7 during at least 3 consecutive cycles). In our population the majority of 
participants was CRA and about 25% were clomiphene-failure patients. 
Because the study clinic is a tertiary referral center, a proportion of these 
patients was treated previously with clomiphene-citrate and/or gonado-
tropins elsewhere. Exclusion criteria were: (1) Thyroid dysfunction (TSH 
< 0.2 mIU/L or TSH > 4.2 mIU/L), (2) bilateral tubal occlusion on hystero-
salpingogram and (3) severe male infertility (sperm concentration < 10 x 
106). This study was approved by the local Ethics Review Committee of 
the Dijzigt Academic Hospital and the Erasmus University. 
Study design: Initial screening included random transvaginal sonography 
(TVS) and blood withdrawal. Patients with peri-ovulatory E2 concentra-
tions (> 400 pmol/L) or luteal P concentrations (P > 1 5 nmol/L) were 
excluded. The ratio of T x 100/SHBG was used to calculate the free 
androgen index (FAI). 
Patients were treated by daily Lm. injections with urinary FSH (HMG 
[Humegon®, N.V. Organon, The Netherlands]) according to a step-down 
protocol (as described below). Monitoring of ovarian response by TVS was 
performed every 2 or 3 days, until human chorionic gonadotropin (hCG 
[Pregnyl®, N.V. Organon, The Netherlands]) was administered. hCG was 
injected intramuscularly as a single dose of 10000 IU on the day at least 
one follicle <:18 mm was observed upon TVS examination. If more than 3 
follicles <:16 mm were present, stimulation was cancelled and the patient 
was advised to use barrier contraceptives. Sonographic monitoring was 
performed using a 6.5 MHz transvaginal transducer (Model EUB-415, 
Hitachi Medical Corporation, Tokyo, Japan). Monofollicular growth was 
defined as one follicle <:16 mm on the day of hCG administration. Treat-
ment was started between cycle day 3 and 5 after a spontaneous or 
progestagen-induced withdrawal bleeding. The starting dose of gonado-
tropins was·2 ampules (= 150 IU) per day. The initial dose was increased 
with Y, ampule per day if ovarian response was absent after 5 days. The 
first decrease in dose by Y, ampule/day was based on TVS visualization 
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of a follicle 21 0 mm ('ovarian response'), which coincides with appearance 
of the dominant follicle during the normal menstrual cycle (Pache et a/., 
1990). Further dose·decrease, each time by Y, ampule/day, was per-
formed every 3 days to a minimum dose of 1 ampule/day. This dose was 
continued until the day of hCG administration. If growth of follicles was 
absent during 10 subsequent days (including one 'step-up' of Y, am-
pule/day on the 5th day), further medication was withheld and a higher 
starting dose was used the next cycle. No luteal support was provided. 
Statistical analysis: Values given are mean ± standard deviation (SO) 
unless stated otherwise. P-values given are two-sided and 0.05 was 
considered the limit of statistical significance. Comparisons of categorical 
data between patient-groups were tested with the x2-test. Continuous 
data were compared using the Mann-Whitney test. Correlation coeffi-
cients given were calculated according to Pearson. Ovulation after hCG 
administration was determined by occurrence of pregnancy, by occurrence 
of a withdrawal bleeding or by sonography and/or mid-luteal P concentra-
tions (P 215 nmollL) in case of uncertainty based on the former criteria. 
Pregnancy diagnosis was confirmed by a positive urinary pregnancy test 
(hCG concentration> 25 IU/L) and ongoing pregnancy rate by sonographic 
evidence of an intra-uterine gestational sac and fetal heartbeat. Ovarian 
hyperstimulation was recognized as patients attending our clinic (within 
2 weeks following the last administration of gonadotropins) with serious 
abdominal discomfort and sonographic evidence for grossly enlarged 
ovaries and increased quantities of free abdominal fluid. Subdivision of the 
study population using clinical, endocrine and sonographic characteristics 
was based on calculated values of these parameters in a normal control 
population as described previously (van Santbrink et a/., 1997a). 
Assays: Blood samples were obtained through venepuncture and centri-
fuged within two hours after withdrawal. Serum was stored at -20°C and 
assayed for FSH and LH by immunoradiometric assay (IRMA) kits provided 
by Medgenix (Fleurus, Belgium), and androstenedione (AD), sex-hormone 
binding globulin (SHBGl, dehydroepiandrosterone sulfate (DHEAS) and 
testosterone (T) by radioimmunoassay (RIA) kits provided by Diagnostic 
Products Corporation (Los Angeles, CAl, as described previously (Fauser 
et a/., 1991). Intra- and inter-assay coefficients of variation were less than 
3% and 8% for FSH, less than 5% and 15% for LH, less than 8% and 
11 % for AD, less than 4% and 5% for SHBG, less than 4% and 6% for 
DHEAS and less than 3% and 5% for T, respectively. 
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3.3.3 Results 
For patient characteristics after initial screening of the study population 
see Table 3. Median duration of infertility was 3 years (range, 1 to 14 
years). Serum prolactin concentrations were elevated in 4 subjects (4%). 
Oligomenorrhea was observed in 70 (72%) of all patients and 67 (69%) 
suffered from a primary infertility. Patients were treated with exogenous 
gonadotropins according to a step-down protocol with a total number of 
induction cycles of 286 and a median number of cycles per patient of 3 
(range, 1 to 13) cycles. Results of ovulation induction in the total study 
group are shown in Table 4. Initial clinical, biochemical, and sonographic 
patient characteristics were compared with treatment results and compli-
cation rates (Table 5). Number of ampules needed and duration of 
gonadotropin administration were influenced by BMI (f = 0.39; P< 0.001; 
f = 0.26, P= 0.01, respectively)' initial FAI (f = 0.24, P = 0.03; P= NS) 
and initial serum E2 concentrations (f= -0.20, P= 0.05; f= -0.23, 
P= 0.03). There was a negative correlation between ovulation rate and 
BMI (f = -0.20, P= 0.05), DHEAS (f = -0.23, P= 0.03), FAI (f = -0.26, 
P=0.02), mean ovarian volume (f=-0.25, P=0.03) and polycystic 
ovaries If = -0.27, P = 0.03). Serum FSH decreased by age (f = 0.20, 
P= 0.05). Cancellation rate was correlated to initial mean ovarian volume 
(f=0.24, P=0.04), FAI (f=0.26, P=0.04) and DHEAS (f=0.24, 
P=0.02). 
Women who conceived did not differ significantly from women who 
did not with regard to anamnestic, clinical, endocrine, or sonographic 
screening parameters (data shown partially in Table 5). Initial screening of 
mean ovarian volume and DHEAS correlated with mono- or multifollicular 
development (see Table 3). Initial serum DHEAS also correlated with 
multiple gestation (f = -0.32; P = 0.04). In women presenting with multi-
follicular growth pregnancy rates were higher IP = 0.03), but comparison 
between multiple pregnancy rates did not reach statistical significance. 
3.3.4 Discussion 
In case initial clinical, endocrine or sonographic screening could predict 
individual treatment response of anovulatory patients with exogenous 
gonadotropins this would be an important step forward in the improvement 
of fertility treatment. It could be the basis for a clinically relevant 
classification of this patient group: with consequences for choice of 
treatment strategy, duration of medication, and intensity of monitoring. 
The present study is a first attempt to determine certain correlations 
between single initial clinical, endocrine, or sonographic characteristics 
and treatment response parameters in gonadotropin induction of ovulation. 
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Table 3 Initial clinical, biochemical and sonographic characteristics 
{mean ± SD} of a group of norma gonadotropic oligo- or amenorrheic 
clomiphene-citrate resistant infertile women and a sub-division of these patients 
based upon monofollicular (not more than 1 follicle ;'16 mm) or multifollicular 
growth on the day of hCG administration during gonadotropin induction of 
ovulation. 
Total Monofol/icular Multifol/icular 
group growth growth 
n = 97 n = 57 n = 40 
Clinical: 
Age (yrs) 29±4 30±4 28±5* 
BMI (kg/m') 26±6 26±5 26±6 
Amenorrhea (%) 28 23 35 
Endocrine: 
FSH (lUlL) 4.3± 1.6 4.4±1.6 4.1 ± 1.2 
LH (lUlL) 6.7±4.5 7.0±4.6 6.5 ±4.3 
AD (nmol/L) 15.6±6.9 16.0 ± 7.2 15.4±6.9 
T (nmol/L) 2.5±1.1 2.5 ± 1.0 2.6±1.2 
DHEAS (f1moI/L) 7.4±3.9 6.6±3.7 8.6±4.1* 
FAI (T x 100/SHBG) 6.3 ±4.6 5.8±4.0 7.2±5.0 
Ultrasound: 
Mean follicle number 13.8 ± 7.3 13.1 ±7.3 15.6 ± 7.4 
Mean ovarian volume (mL) 12.4±5.3 11.3±4.5 14.5 ±6.1* 
Total stroma score 4± 1 4± 1 4±1 
.p~ 0.05 (mono vs, multifollicular growth, significance tested with Mann-Whitney), 
Observations in the present study include BMI, initial serum FAI, and E2 
correlating with total number of ampules needed; 8MI and serum E2 
correlated with duration of induction; initial serum OH EAS and ovarian 
volume correlated with multifollicular development; while OHEAS, FAI, 
polycystic ovaries, and ovarian volume correlated with ovulation rate. 
Negative predictive factors of treatment results for ovulation induction 
as well as for controlled hyperstimulation preceding IVF reported in 
literature are: (1) advanced patient age (Oor et al., 1980; Padilla et al., 
1989; Tan et al., 1992; McClure et al., 1993; Check et al., 1994), (2) 
obesity (McClure et al., 1992; Chong et al., 1986; Hamilton-Fairley et al., 
1992; Kiddy et al., 1992), (3) decreased ovarian reserve (higher basal 
serum FSH [Muasher et al., 1988; Toner et al., 1991] or low serum E2 
[McClure et al., 1993], poor FSH clomiphene-citrate challenge test [Tanbo 
et al., 1992] or initial small ovarian volume on ultrasound [Syrop et al., 
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Table 4 Treatment outcome of gonadotropin ovulation induction in a group of 
normogonadotropic oligo- Of amenorrheic infertile women with clomiphene-
citrate resistance or clomiphene-citrate failure and after subdivision in patients 
presenting with monofollicular (not more than 1 follicle 2::16 mm) or multi-
foilicular growth on the day of hCG administration. 
Total Monofollicular Multifollicular 
group growth growth 
n ~97 n~57 n~40 
Number of cycles 286 149 137 
Max. daily dose (amp.)' 5.5 (1.5-5.5) 5.5 (1.5-5.5) 3.0 {1.5-3) 
Total no. of ampules needed4- 14 (5-33) 14 (5-33) 14 (7-33) 
Treatment duration (days) * 9 (5-20) 9(5-16) 9 (6-20) 
Ovulation rate (%) 83 86 83 
Pregnancies (%) 49 44 56' 
Mult. pregnancies (%) 17 12 25 
Abortions (%) 13 4 25 
* Median and range 
'p ~ 0.03 
None of the remaining comparisons between both groups reaches statistical significance, 
possibly due to small numbers. 
1995; Lass et al., 1997)), and (4) elevated serum androgens (OHEAS, T 
or FAI [Farhi et al., 1997]). 
The effects of advanced patient age described in literature are: less 
successful stimulation, reduced pregnancy rates (Oor et al., 1980), and 
reduced live birth rates (Padilla et al., 1989; Tan et al., 1992; McClure et 
al., 1993; Check et al., 1994). We were not able to detect any of these 
consequences of patient age for results of step-down induction of 
ovulation in the present study group (Table 5), although a tendency was 
observed that older age was associated with more patients exhibiting 
monofoilicular growth (Table 3). 
Obesity has also been correlated with negative treatment outcome. In 
the present study, as in literature, obese patients needed more gonado-
tropins and a prolonged induction period (McClure et al., 1992; Chong et 
al., 1986), but reduced ovulation rates and ongoing pregnancy rates 
(Hamilton-Fairley et al., 1992) could only be confirmed for the former issue 
(Table 5). Negative influence of obesity on treatment results of ovulation 
induction has been described as being reversible with weight reduction 
(Kiddy et al., 1992). 
Reduced ovarian reserve (high basal cycle day 3 FSH [Muasher et al., 
1988; Toner et al., 1991], or excessive FSH response to clomiphene-cit-
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rate challenge test (Tanbo et a/., 1992]) has been described as being a 
problem especially for controlled hyperstimulation in IVF resulting in less 
ovarian responsiveness and reduced pregnancy rates. For gonadotropin 
induction of ovulation the impending ovarian failure problem has not been 
described related to FSH concentrations but to basal E2 concentrations 
(McClure et a/., 1993). In the present study, low serum E2 concentrations 
are observed to be related to an increased amount of gonadotropins needed 
and a longer induction period. In the literature an association with increased 
miscarriage rates was also described (McClure et a/., 1993). A different 
approach may be to determine ovarian reserve by ovarian volume on 
ultrasonography. Indeed, decreased ovarian volume is associated with 
poor IVF outcome: less oocytes and embryos (Syrop et a/., 1995) or 
increased total amount of gonadotropins needed, higher cancellation rate 
due to poor response, and less follicles and oocytes obtained (Lass et a/., 
1997). Smaller initial ovarian volume in the present ovulation induction 
study was associated with lower initial serum E2, less preovulatory follicles 
(more monofollicular growth) but higher cancellation rates which confirms 
findings in IVF studies. Patient age did not match with above-mentioned 
parameters for ovarian aging but was associated with a higher percentage 
of monofollicular growth. 
Good responders in ovulation induction (patients treated according to 
a low· dose step·up regimen with high FSH:LH ratio and increased numbers 
of follicles <:8 mm on treatment day 8) were prone to develop multifollicular 
growth (Farhi et a/., 1997). This may be partly explained by accumulation 
of FSH in the late follicular phase (van Santbrink et a/., 1997b). Multi-
follicular growth and high preovulatory E2 concentrations in ovulation 
induction were reported not to be associated with multiple gestation 
(Goldenberg et a/., 1994) but did correlate with changes in ovarian 
hyperstimulation (Blankstein et a/., 1987). These findings are in concor-
dance with observations in the present study: the number of preovulatory 
follicles on the day of hCG administration was correlated with higher 
pregnancy rates but did not correlate with higher multiple gestation rates. 
Since no severe ovarian hyperstimulation did occur in the present study, 
no conclusions can be drawn on this subject. 
Patients with elevated androgens (DHEAS, T or FA!) in a recurrent 
miscarriage group presented with higher chances of miscarriage in a 
subsequent spontaneous pregnancy (Tulppala et a/., 1993). Surprisingly, 
single sample LH serum concentrations in the above mentioned study had 
no predictive value for pregnancy outcome in this particular group. This is 
in contrast with earlier reports in which high LH was suggested as a risk 
factor for miscarriage (Regan et a/., 1990; Hamilton·Fairley et a/., 1991; 
Balen et a/., 1993). Risk factors for miscarriage could not be identified in 
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our study group ITable 5). This may be due to the relatively small number 
of patients included. Elevated androgens IFAI and DHEAS) in the present 
ovulation induction study were associated with decreased ovarian re-
sponse Imore gonadotropins needed, decreased ovulation rate, and higher 
cancellation rate). 
In conclusion this study suggests that obesity, ovarian aging lIow basal 
E2 serum concentrations and small initial ovarian volume), polycystic 
ovaries, and elevated serum androgens IDHEAS and FAil may be associ-
ated with impaired treatment response in a group of normogonadotropic 
oligo- or amenorrheic infertile women with clomiphene-citrate resistance 
or failure, treated with exogenous gonadotropins according to a step-down 
dose regimen: more gonadotropins are needed for a prolonged period and 
ovulation rates are lower. 
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Gonadotropin induction of 
ovulation 
4.1 GENERAL INTRODUCTION 
Induction of ovulation using exogenous gonadotropins is generally indi-
cated in patients with normogonadotropic anovulatory infertility who failed 
to ovulate or conceive during previous anti estrogen treatment. Alterna-
tively, ovarian cautery by laser may also be applied. The aim of this 
treatment modality is to approach normal conditions as closely as possible, 
i.e. maturation and ovulation of a single dominant follicle and subsequent 
singleton pregnancy. However, although gonadotropin therapy has been 
shown to be rather successful in terms of ovulation rates (reported in 
literature between 60-100%) and cumulative pregnancies (reported be-
tween 20-75%), complication rates are high. Major complications include 
multiple pregnancies and ovarian hyperstimulation. As these complications 
have been shown to be related to the magnitude of multi-follicle develop-
ment, efforts have been made to reduce the number of follicles that reach 
full maturity. Our group has focused on a 'step-down' dose regimen that 
more closely mimics FSH serum concentrations during the follicular phase 
of the normal menstrual cycle. Previous work (Schoot et al., Thesis 1995) 
has been the basis for development and modification of the step-down 
dose regimen. It was proposed on the basis of observations in a limited 
patient group that a step-down dose regimen for induction of ovulation 
using exogenous gonadotropins could be an effective treatment alternative 
and may lead to reduced complication rates (Schoot et al., Thesis 1995). 
The objective of the following studies was to investigate the clinical 
usefulness of a gonadotropin step-down dose regimen for induction of 
ovulation in normogonadotropic clomiphene-resistant anovulation on a 
large scale and to compare this treatment protocol in randomized prospec-
tive fashion with a low-dose step-up protocol. The objective in the latter 
study was to assess potential differences in treatment duration and 
treatment dose, ovarian stimulation (late follicular FSH serum profile) and 
response (serum E2 concentrations and number of dominant follicles on 
the day of hCG administration). 
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4.2 GONADOTROPIN INDUCTION OF OVULA TlON USING A 
STEP-DOWN DOSE REGIMEN: SINGLE-CENTER CLINICAL 
EXPERIENCE IN 82 PA TIENTS 
4.2.1 Introduction 
Since the introduction of urinary gonadotropins in clinical medicine thirty 
years ago, this treatment modality has been the primary choice for infertile 
patients suffering from clomiphene-resistant normogonadotropic anovula-
tion. Although indisputably effective, these compounds carry important 
risks, chiefly ovarian hyperstimulation (Stephenson, 1991; Navot et a/., 
1992) and multiple pregnancies (Derom et a/., 1993), associated with 
considerable obstetric complications (Levene et a/., 1992; Callahan et a/., 
1994). 
In the past, various treatment schedules have been reported including 
single dose, intermittent or multiple fixed doses, as well as incremental or 
decremental dose regimens (Taymor eta/., 1967; Thompson et a/., 1970). 
At present, the most frequently used administration schedules are 'step-
up' regimens, i.e. increasing doses of exogenous gonadotropins through 
daily i.m. injections until ovarian response is considered to be 'sufficient'. 
In an attempt to diminish complication rates, conventional step-up regi-
mens were modified to 'low-dose, step-up' regimens (Seibel et a/., 1984; 
Buvat et a/., 1989; Hamilton-Fairley et a/., 1991) starting with a lower 
initial dose (Jt, or 1 ampule/day) and with small increments (Jt, ampule) at 
weekly intervals. Using low-dose regimens, improved clinical outcome was 
reported compared to conventional step-up regimens. 
The half-life of exogenous urinary FSH in females has been reported to 
be -44h (Diczfalusy eta/., 1989; Mannaerts eta/., 1993), and if equal 
daily doses are administered, steady state serum FSH concentrations are 
reached after 5 to 7 days (Mizunuma et a/., 1990; Schoot et a/., 1994; 
van Heusden et a/., unpublished data). It should therefore be considered 
that during step-up regimens elevated FSH serum concentrations may 
occur during the late follicular phase which may interfere with selection 
of a single dominant follicle (Fauser et a/., 1993b; Fauser, 1994; van der 
Meer et a/., 1994). It has been shown that the magnitude of FSH 
accumulation determines ovarian (hyper)response (Ben Rafael et a/., 
1986). In contrast, in the normal menstrual cycle the dominant follicle 
shows a decreased dependency of FSH (Messinis et a/., 1990; Hall et a/., 
1991; van Santbrink eta/., 1995), and reduced FSH concentrations during 
the late follicular phase were found to be essential for monofollicular 
development in the monkey model (Zeleznik et a/., 1985). Our previous 
studies have shown that step-down gonadotropin dose regimens result in 
a significant (40%) reduction in serum FSH concentrations (Schoot et a/., 
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1995) and closely resemble decreasing FSH concentrations in spontane-
ous cycles (van Santbrink et al., 1995). This prospective, single-center, 
non-comparative study was undertaken to investigate the clinical useful-
ness of a gonadotropin step-down regimen for the induction of ovulation 
in women suffering from clomiphene-resistant anovulation. 
4.2.2 Patients and methods 
Between 1 991 and 1993, 82 patients attending our Fertility Clinic 
presenting with oligomenorrhea (cycle length > 35 days) or amenorrhea 
(no vaginal bleeding for at least 6 months), FSH serum concentrations 
within normal limits (between 1 and 10 lUlL) and infertility (duration 
median 3 years, range, 1 to 12 years) were included in this study. Included 
patients had a median age of 29 years (range, 20 to 42 years), body mass 
index (BMI, weight divided by height squared) was 24 kg/m2 (range, 19 
to 42 kg 1m2), median luteinizing hormone (LH) concentration was 5.21U/L 
(range, 1.1 to 14.5 lUlL) and testosterone (T) concentration was 1.9 nmol/L 
(range, 0.4 to 5.8 nmoI/L). The protocol was approved by the Human 
Subject Committee of the Dijkzigt Academic Hospital I Erasmus University. 
All participants suffered from clomiphene-resistant anovulation, which 
was defined as failure to ovulate or to conceive, despite increasing doses 
of clomiphene citrate (up to 150 mg/day, from cycle day three to seven) 
during at least 3 consecutive cycles. Since this clinic is a tertiary referral 
center, a proportion of these patients was previously treated with gonado-
tropins elsewhere. Exclusion criteria were; (1) hypergonadotropic (FSH 
> 10 lUlL) or hypogonadotropic (FSH < 1 lUlL) anovulation, (2) anovula-
tion in the presence of thyroid dysfunction (thyroid-stimulating hormone 
< 0.2 or >4.2 mUlL) or hyperprolactinemia (prolactin> 15 nmoI/L), (3) 
bilateral tubal occlusion on hysterosalpingogram, and (4) severe male 
infertility (sperm count < 10 x 106 ImL). The following additional fertility 
problems were included in this study; cervical hostility in 8 cycles (3.3%) 
and male subfertility (sperm count 10-40 x 106 spermatozoa/mL, motility 
< 50%, or both) in 18 cycles (7.6%). Infertility was primary in 56 patients 
(68%), while a secondary infertility was found in 26 patients (32%). 
Patients were treated by daily intramuscular injections with gonado-
tropins (HMG; Humegon@, NV Organon Int., Oss, The Netherlands) in 93% 
of cycles and at random with purified urinary FSH (Metrodin@, Sera no, 
Weesp, The Netherlands) in 7% of cycles according to a step-down dose 
regimen (as described below). Monitoring of ovarian response by trans-
vaginal sonography (TVS) was performed every 2 or three days, until 
human chorionic gonadotropin (hCG; Pregnyl@, NV Organon Int.) was 
administered. Sonographic monitoring was performed using a 6.5 MHz 
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transvaginal transducer (Model EUB-415; Hitachi Medical Corporation, 
Tokyo, Japan). At the beginning of this study, in 43 cycles (18% of total 
cycles) patients were pretreated with gonadotropin-releasing hormone 
(GnRH) agonists (Buserelin; Suprefact®, Hoechst, Amsterdam, The Nether-
lands]) for 3 weeks (3 x 400 fig/day intranasally)' which was continued 
during gonadotropin administration until the day of hCG administration 
(Schoot et a/., 1992b). 
For each patient, blood samples for initial screening were randomly 
taken through vein puncture, centrifuged within 2 h of withdrawal and 
stored at -20°C until assayed. Serum was assayed for immunoreactive 
FSH, LH, T and Progesterone (P), as described previously (Fauser et a/., 
1991 ). 
Step-down protocol: Treatment was started between cycle days 3 and 5 
after a spontaneous or progestagen-induced withdrawal bleeding. The 
starting dose of gonadotropins was dependent on the BMI and patients 
were divided into 3 groups: (I) BMI 19-23 kg/m2 (n = 41; 50%), 1 Y, 
ampule (= 1131U) per day; (Ii) 8MI 23-28 kg/m2 (n = 28; 34%),2 ampules 
(= 150 IU) per day; and (iii) BMI > 28 kg/m2 (n = 13; 16%), 2 Y, ampules 
(= 1881U) per day. This approach was based on the observation that 
following a single dose of gonadotropins, maximum serum FSH concen-
trations were dependent on body weight (Mannaerts et a/., 1993). The 
first decrease in dose by Y, ampule/day, was based on sonographic 
visualization of a follicle> 9 mm, which coincides with appearance of the 
dominant follicle during the normal menstrual cycle Wac he et a/., 1990). 
The initial dose was increased with Y, ampule/day if ovarian response was 
absent after 5 days. Further dose-decrease, each time by Y, ampule/day, 
was performed every 3 days to a minimum dose of 1 ampule/day. This 
dose was continued until the day hCG could be administered. During the 
follicular phase, the continued growth of follicles was monitored by TVS. 
hCG was injected Lm. as a single dose of 10000lU on the day that at 
least one follicle :::18 mm was present upon TVS examination. If there 
were more than 3 follicles :::16 mm in diameter, stimulation was cancelled 
and the patient was advised to use barrier contraceptives. If the growth 
of follicles was absent during 10 subsequent days (including one 'step-up' 
of Y, ampule/day on the 5th day), further medication was withheld and a 
higher starting dose was used the next cycle. No luteal support was 
provided. 
Data analysis: Values given are mean ± SO unless stated otherwise. 
Because no significant difference was found in clinical and sonographic 
parameters between the group with and without GnRH agonist co-treat-
ment and patients treated with HMG or pFSH (tested using the 
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Mann-Whitney or Wilcoxon test), results were pooled. Pvalues given are 
two-sided, and 0.05 was considered the limit of statistical significance. 
Differences between patient groups were tested using the Mann-Whitney 
or Student's t-test. The follicular phase was arbitrarily defined as the 
interval between first day of gonadotropin medication and the day 
following hCG administration (hCG + 1; presumed ovulation). The luteal 
phase was defined as the interval between day of hCG + 1 and the first 
day of subsequent menses. Distribution of ovarian follicles was arbitrarily 
classified in categories according to diameter: 10-12, 12-16 and ;0,16 mm. 
Ovulation after hCG administration was determined by a viable pregnancy, 
the occurrence of withdrawal bleeding or sonography andlor mid-luteal P 
concentrations in case of uncertainty of the former criteria. Pregnancy 
diagnosis was confirmed by a positive urinary pregnancy test (hCG 
concentration > 25 lUlL) and ongoing pregnancy rate by sonographic 
evidence of an intrauterine gestational sac and a fetal heart action. Ovarian 
hyperstimulation was recognized in patients attending our clinic (within 2 
weeks following the last administration of gonadotropins) with serious 
abdominal discomfort and sonographic evidence for grossly enlarged 
ovaries and increased quantities of free abdominal fluid. 
4.2.3 Results 
In all, 82 patients were treated with exogenous gonadotropins for a total 
of 234 cycles. The median cycle number per patient was 2 (range, 1 to 
7). Co-treatment with GnRH analogues was used in 43 initial cycles (18% 
of total); no statistically significant differences between the group with 
and without co-treatment were found with regard to the duration of 
stimulation (11.3 vs. 10.5 days), the total number of ampules of gonado-
tropin used per cycle (15.5 vs. 13.0 ampules), the luteal phase length 
(12.4 vs. 13.3 days), and the pregnancy rate (5/43 vs. 32/191). In 16 
cycles (7%), purified FSH was given instead of HMG; no statistically 
significant differences in both treatment groups with regard to treatment 
outcome were found (data not shown). In 36 (15%) cycles the initial dose 
of HMG was increased. 
In the overall study group the duration of ovarian stimulation until 
ovulation was 10.6 ± 3.6 days and 13.5 ± 6.9 ampules were adminis-
tered. The luteal phase had a duration of 13.1 ± 4.2 days. For more 
detailed information see Figure 10. hCG was given in 214 (92%) cycles. 
One cycle was considered to be anovulatory because of low mid-luteal P 
concentrations (2 nmoI/L). In 10 (4%) cycles hCG was withheld because 
of cancellation of gonadotropin medication due to a lack of ovarian 
response. In the additional 10 (4%) cycles more than 3 follicles ;0,16 mm 
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Figure 10 Distribution of duration of treatment phase (duration of initiation of 
gonadotropin medication until one day following hCG administration (top); the 
required number of ampules of gonadotropins per cycle (middlel; and the 
duration of the luteal phase (bottoml in a total of 21 3 ovulatory cycles using a 
step-down dose regimen for induction of ovulation in 82 clomiphene-resistant 
anovulatory women (outlyers are excluded). 
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Figure 11 Distribution of number of follicles of 10-1 2 mm (top); 12-16 mm 
(middle); and ;>16 mm (bottom) in diameter on the day of hCG administration 
in 213 ovulatory cycles following a gonadotropin step-down dose regimen for 
induction of ovulation in 82 clomiphene-resistant anovulatory women. 
51 
DEC REM ENTAL FSH AND SINGLE DOMINANT FOLLICLE SELECTION IN THE HUMAN 
were present. The ovulation rate was 91 %. On the day of hCG admini-
stration the diameter of the leading follicle was 19.5 ± 1.6 mm, there were 
1.4 ± 0.7 follicles 216 mm in diameter per ovulatory cycle, in 131 (62%) 
cycles there was only one follicle 216 mm (monofollicular growth). and in 
208 (98%) cycles one or two follicles 216 mm were present (Figure 11). 
In 39 cycles (17%). luteal serum P concentrations were determined: the 
median value was 50 nmol/L. There were 4 cases of ovarian hyperstimu-
lation (1.7%). for which in 2 cases clinical attendance (conservative 
management) was necessary for severe abdominal discomfort. In one of 
these patients, ovarian hyperstimulation developed although hCG was 
withheld. In this patient the numbers of larger (216 mm) and intermediate 
(12-16 mm) follicles were 8 and 4, respectively. In the other three patients 
the mean numbers of larger (216 mm) and intermediate (12-16 mm) 
follicles were 2 and 8 on the day of hCG administration. None of these 
four women were pregnant. The overall pregnancy rate per ovulatory cycle 
was 47% after 7 months, as determined by life-table analysis. The 
pregnancy rate per cycle was 16% for all started cycles and 17% for 
ovulatory cycles. A total of 37 pregnancies occurred, of which 2 were 
twins and 1 was triplet (multiple pregnancy rate of 8%). A viable 
pregnancy was confirmed by sonography in 30 (81 %) of the 37 chemical 
pregnancies. The ongoing pregnancy rate was 13% per started induction 
cycle and 14% per ovulatory cycle. The overall singleton ongoing preg-
nancy rate was 12 % per cycle and 13 % per ovulatory cycle (see also 
Table 6). 
No significant differences were found between non-pregnant and 
pregnant women with regard to age, SMI, LH concentration, T concentra-
tion or the number of follicles present in the ovary before treatment (data 
not shown). 
4.2.4 Discussion 
Although effective, the induction of ovulation using exogenous gonado-
tropins in step-up dose regimens is still associated with considerable 
complications, chiefly multiple pregnancies and ovarian hyperstimulation. 
In this respect, low-dose step-up regimens have been advocated recently, 
which offer the advantage of reduced complication rates. However, the 
latter dose regimen seems to be at the cost of a prolonged duration of 
medication and an overall decrease in pregnancy rates, at least in the hands 
of some clinical investigators (Hull, 1991). It should also be mentioned 
that even during low-dose step-up protocols, a significant incidence of 
ovarian hyperstimulation has been reported (Suvat et 81., 1989; Herman 
et 81., 1993). The low-dose step-up approach is based on the FSH 
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Table 6 Comparison of ovarian response and clinical outcome following three different dose regimens for gonadotropin induction 
of ovulation. 
Step-up Low-dose, step-up Step-down 
Dor Hulin Buvat Hamilton-F. Hul/ b Balen vSantbrink 
11980} (7997) (7989) (7997) (7997) (7994) (799S) 
Study design single-center review single-center single-center review single-center single-center 
comp.c non-comp,d comp.c non-comp.d non-comp.d non-comp.d non-comp.d 
Number of patients 348 111 23 100 144 103 82 
Number of cycles 1144 210 44 401 459 603 234 
Duration treatment phase (days) n.r.c n.r. 16 14 n.r. n.r. 11 
Ampules per cycle n.r. n.r. 19 19 n.r. n.r. 14 
Ovulation rate (%) n.r. 78 70' 72' 74 68h 91 i 
'Monofollicular' cycles 
% of ovulatory cycles: n.r. n.r. 84i ]3k n.r. n.r. 62' 
% of all started cycles: n.r. n.r. 59i 55k n.r. n.r. 56' 
Pregnancy rate (%): 
* per started cycle 7 23 16 11 11 14 16 
*per ovulatory cycle n.r. 30 23 16 15 20 17 
Cumulative pregn. rate (%) 50 n.r. n.r. 55 n.r. 73m 47 
Multiple pregn. rate (%) n.r. 23 0 4 11 18 8 
Ongoing singleton pregn. rate (%) n.r. 17 14 7 10 9 12 
Abortion rate (%) n.r. 17 14 32 39 16 19 
OHSS rate (%) n.r. n.r. 5 n.r. 2 
"Combined data of 6 single-center studies; bcombined data of 6 single-center studies; Cstudy was not prospective, randomized; dnon-comp. = non-comparative; °n.r. 
= not reported; f21 % cancelled due to multifoll. development; 9cancellation only due to m,ultifol1. development (low progesterone and no ovarian response 24%); 
hcancelled due to multifoll. development (8%), non-response (8%) and no ovulation (16%); 'cancelled due to mu!tifoll, development (4%) + non-response (4%) and 
low progesterone (= 1 %); i1 follicle ~, 5 mm on day of hCG administration; k, follicle ;?:'8 mm on day of hCG administration; I, fo!!ic!e~' 6 mm on day of hCG 
administration; matter 12 cycles. 
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'threshold' concept, introduced in 1978 by Brown (Brown, 1978), indi-
cating that a threshold concentration of serum FSH should be surpassed 
to elicit an ovarian response. Multifollicular growth might be associated 
with a higher (and prolonged) elevation of FSH concentrations above the 
threshold (van der Meer et al., 1994). The FSH 'gate' (Baird et al., 1987) 
or FSH 'window' (Fauser et al., 1993a; Fauser, 1994) concept adds the 
element of time to the threshold theory. The longer the threshold is 
surpassed, the more follicles will be stimulated to ongoing growth and 
dominant follicle development. 
The 'step-down' approach for gonadotropin induction of ovulation was 
subsequently developed aiming at serum FSH concentrations to be above 
the threshold for just a restricted period of time, resulting in a narrow FSH 
window. However, the FSH threshold may vary considerably in PCOS 
patients, which makes it difficult to choose an adequate starting dose. It 
was hypothesized that the dominant follicle will continue its development 
due to an enhanced sensitivity for FSH, whereas serum FSH concentra-
tions fall below the threshold for less mature follicles. In a previous study 
by our group, serum FSH concentrations were monitored daily in a 
subgroup of 22 patients using a similar step-down gonadotropin dose 
regimen (with GnRH agonist co-treatment), which did confirm the occur-
rence of a significant (P=O.OO1) decrease (10% per day for 4 days) in 
serum FSH concentrations from median maximum concentrations of 
7.6 lUlL to 4.7 lUlL on the day of hCG administration (Schoot et al., 1995). 
Other groups have reported that cycles prone to develop ovarian hyper-
stimulation could be 'rescued' by withholding HMG for several days 
(Rabinovici et al., 1987). Hence, a late and pronounced decrease in serum 
FSH concentrations prevents the further development of medium-sized 
follicles, whereas large follicles still ovulate following delayed hCG admini-
stration. This approach, presently referred to as 'coasting', in fact closely 
resembles a step-down regimen. Mizunuma et al. (1991) reported a small 
and uncontrolled study (n = 9) using a step-down regimen. A short mean 
stimulation phase (7.4 days), a pregnancy rate per cycle of 16% (multiple 
pregnancy rate of 13%), and a hyperstimulation rate of 7% were reported. 
The small number of patients and the selection criteria used to include 
patients (admission for step-down treatment after successful induction of 
ovulation during a step-up regimen in the preceding cycle) limit the 
conclusions that can be drawn from this study. Also, no explanation was 
provided for the high cancellation rate of 20%. Preliminary data were 
reported recently (Steinkampf et al., 1993) from a large (n = 175) random-
ized prospective multicenter study comparing a step-down regimen with 
an ascending dose schedule. The mean numbers of follicles ;0:16 mm in 
diameter on the day of hCG administration (at least 1 follicle ;0:16 mm in 
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diameter) were similar (1.5 follicle) in both groups tested. Ovulation and 
complication rates were equal, but pregnancy rates in the step-down group 
were significantly reduced (7.1 compared to 15.7% in the ascending dose 
group). However, the used fixed starting dose of 3 ampules/day may have 
been too high (Schoot et a/., 1992b), and a fixed decrease of the dose to 
1 ampule/day after 3 days does not take into account individual differences 
in the FSH threshold (Brown, 1978; Polson et a/., 1987; Fauser et a/., 
1 993a) and may result in serum FSH concentrations which drop too early 
and too rapidly. These considerations may explain the reported poor 
treatment outcome of the step-down dose regimen. For a comparison of 
clinical results of the presently applied decremental dose regimen versus 
(low dose) step-up regimens reported in the literature, see Table 6. 
In conclusion, our study shows for the first time that a step-down 
regimen for gonadotropin induction of ovulation can serve as a safe and 
successful treatment alternative in patients with clomiphene-resistant 
anovulation. We feel that the presented data using the step-down 
approach, with starting doses of 1 Y, to 2 Y, ampules/day based on body 
weight, demonstrate convincingly that follicles grow and ovulate and 
pregnancies occur, and therefore challenge the dogma of step-up regi-
mens. The duration of stimulation, the amount of gonadotropins needed, 
and the clinical outcome (in terms of both success and complication rates) 
appear favorable. It should be stressed, however, that observations from 
non-comparative studies should be interpreted with great care. Statistically 
meaningful comparisons between different studies cannot be made due 
to: (i) the non-comparative nature of the great majority of studies where 
larger patient numbers are involved; (ii) selection bias due to different 
patient populations studied; in this study, for example, exclusion criteria 
were less strict than in most reported studies (Hamilton-Fairley et a/., 
1 991), and because our clinic is a tertiary referral center some patients 
were treated unsuccessfully elsewhere before attending our clinic; (iii) 
differences in monitoring of ovarian response; and (iv) different criteria 
being used for calculating success and complication rates. Therefore, one 
should be cautious with the clinical introduction of this dose regimen. At 
present, the step-down approach may be reserved for PCOS women who 
exhibit pronounced multiple follicle development during step-up regimens. 
Because of ongoing concern with regard to the increased incidence of 
multiple gestation and the resulting complications (Callahan et a/., 1994), 
which are largely due to the induction of ovulation (Derom et a/., 1993), 
we strongly believe that this approach deserves further consideration. 
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4.3 URINARY FOLLlCLE·STlMULATING HORMONE FOR 
NORMOGONADOTROPIC CLOMIPHENE·RES/STANT 
ANOVULA TORY INFERTILITY: PROSPECTIVE, RANDOMIZED 
COMPARISON BETWEEN LOW·DOSE STEP·UP AND 
STEp·DOWN DOSE REGIMENS 
4.3.1 Introduction 
Since the early 1960s, infertile patients with anovulation have been treated 
with human menopausal gonadotropin and human chorionic gonadotropin 
(hCG). This treatment modality has proven to be effective (Ginsburg et 
al., 1991), although associated complications (principally multiple preg-
nancies and ovarian hyperstimulation) remain an issue of major concern 
(Sagle et al., 1991; Navot et al., 1992; Levene et al., 1992; Fauser et al., 
1997a). Based on Brown's theory (Brown, 1978), conventional step-up 
regimens have been modified to a low-dose step-up protocol (Buvat et al., 
1989; White et al., 1996). A lower initial dose of a Y, or 1 ampulelday is 
used, and the dose is increased by small increments (y, ampule) at 1 to 
2-week intervals in an attempt to slowly and prudently surpass the 
individual FSH threshold. In both treatment regimens the administered 
dose of gonadotropins is kept constant from the day of sufficient ovarian 
response on ultrasound (Buvat et al., 1989; Sagle et al., 1991; White et 
al., 1996), until the day of hCG administration to induce ovulation. The 
risk of multiple follicle development and subsequent complications is 
reduced with low-dose step-up as compared to conventional step-up 
regimens (Buvat et al., 1989; White et al., 1996). However, low-dose 
step-up regimens may also lead to multiple follicle development (Herman 
et al., 1993) and appear to be more time consuming (Fauser et al., 1997a). 
Due to the long half-life of FSH (Mizunuma et al., 1991; Mannaerts et al., 
1993), fixed daily doses of gonadotropin preparations may result in 
accumulation and, therefore, increased FSH serum concentrations in the 
late follicular phase. It has been reported that the magnitude of FSH 
accumulation determines ovarian hyperresponse in patients treated with 
in vitro fertilization (Ben-Rafael et al., 1986). 
In contrast, during the normal menstrual cycle the dominant follicle 
continues to grow despite decreasing FSH serum concentrations (Messinis 
et al., 1990; Hall et al., 1991; van Santbrink et al., 1995a). Diminishing 
concentrations of FSH during the follicular phase have been shown to be 
essential for monofollicle development in the monkey-model (Zeleznik et 
al., 1985) as well as in the human (Lolis et al., 1995). It is possible that 
elevated late follicular phase FSH concentrations during step-up regimens 
unintentionally interfere with single dominant follicle selection (Fauser, 
1994). Our previous studies have shown that a step-down gonadotropin 
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dose regimen more closely resembles decreasing FSH concentrations 
found in spontaneous cycles (van Santbrink et al., 1995a; Schoot et al., 
1995; van Dessel et al., 1995), and can serve as a safe and successful 
treatment alternative for women suffering from clomiphene-resistant 
anovulation (van Santbrink et al., 1995b). This study is the first prospec-
tive randomized comparison between a low-dose step-up and a step-down 
protocol for gonadotropin induction of ovulation. The objective was to 
assess potential differences in treatment duration and dose, ovarian 
stimulation, and response. 
4.3.2 Patients and methods 
Subjects: Inclusion criteria were: infertility (seeking pregnancy;O:1 year), 
cycle abnormalities (oligomemorrhea [interval between menstrual bleed-
ings > 35 days] or amenorrhea [no bleeding for at least 6 months]), FSH 
serum concentration within the normal range (FSH 1-10 lUlL), 
clomiphene-resistance (defined as failure to ovulate or conceive after 
clomiphene treatment up to a daily dose of 150 mg from cycle day 3 to 
7 during at least 3 consecutive cycles), age 20-40 years, normal PRL 
« 15 nmol/L) and TSH (0.2 mlU/L < TSH < 4.2 mIU/L) serum concentra-
tions, absence of evidence of bilateral tubal occlusion as assessed by 
hysterosalpingogram, and absence of severe oligospermia (sperm count 
< 1 0 x 106 spermatozoa/mL). 
Thirty-seven patients attending our Fertility Clinic fulfilling above men-
tioned criteria were included in this study. Patients included (see Table 7) 
had a median age of 29 years (range, 20 to 40 years), median body mass 
index (weight divided by height squared) was 25 kg/m 2 (range, 18 to 
41 kg/m 2 ), and the median duration of infertility was 3 years (range, 2 to 
7 years). The protocol was approved by the local human subject committee 
and informed consent was obtained from all participants. 
Study design: This was a prospective, randomized, single-center study 
comparing a low-dose step-up with a step-down dose regimen for 
induction of ovulation with urinary FSH. Initial screening was performed 
within 2 months before inclusion. Initial screening included random blood 
withdrawal and transvaginal sonography (TVS). Sonographic monitoring 
was performed by a single observer (EJPvS), using an ultrasound machine 
(Model EU8-415, Hitachi Medical Corporation, Tokyo, Japan) with 
6.5 MHz transvaginal transducer. The ovaries were localized in relation to 
the iliac vessels. Follicles appeared as round or ovoid translucent structures 
;0:2 mm in diameter. Follicle number was established by scanning each 
ovary from the inner to the outer margin in longitudinal cross-section. The 
ovarian volume was estimated according to the following formula: 
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Y, (AxBxC), where A is the longitudinal diameter, B the antero-posterior 
diameter and C the transverse diameter of the ovary. Mean follicle number 
and mean ovarian volume were calculated from the sum of the left and 
right values divided by two. Ovarian stroma echogenicity was scored as 
1 (normal), 2 (moderately increased), and 3 (markedly increased) as 
described by Pache et al. (1990). Total stroma count was the combined 
stroma score of both ovaries. For each patient, blood samples for initial 
screening were randomly taken through venepuncture, centrifuged within 
2 h after withdrawal, and stored at -20°C until assayed. Before entering 
the protocol, serum from each patient was assayed for immunoreactive 
FSH, LH (normal range 1.3-6.9IU/L [van Santbrink et al., 1997a]), E2 , 
testosterone (T), androstenedione (AD), sex-hormone binding globulin 
(SHBG) and progesterone (P) as described previously (Fauser et al., 1991). 
After inclusion, patients were randomized by receiving a study number 
corresponding to a sealed envelope containing the protocol to be followed. 
Gonadotropin treatment was started 3-5 days after the initiation of a 
spontaneous or progestagen-induced withdrawal bleeding. Patients re-
ceived daily i.m. injections of purified urinary FSH (Follegon®, NV Organon, 
Oss, The Netherlands) from a single batch (no.: 74029003). Monitoring 
of ovarian response by TVS was performed every 2 or 3 days until hCG 
(Pregnyl®, NV Organon) was administered. hCG was injected i.m. as a 
single dose of 10000 IU on the day upon which at least one follicle ;0,18 mm 
in diameter was observed by TVS examination. If more than 3 follicles 
;0,16 mm were present, stimulation was cancelled, and the patient was 
advised to use barrier contraceptives. During the study, blood samples 
were obtained on the day treatment was initiated, the day of sufficient 
ovarian response, the day of hCG injection, and 3 and 7 days thereafter. 
Sufficient ovarian response was defined as visualization of a follicle 
;0,10 mm by TVS, which coincides with the appearance of the dominant 
follicle in the normal menstrual cycle Wache et al., 1990; van Santbrink 
et al., 1995a). FSH injections were administered between 0800-1200 h. 
Blood withdrawal was performed just before gonadotropin injection, i.e. 
24 h after the previous injection. During treatment, the ovarian response 
was monitored by TVS only. 
Low-dose step-up protocol: The starting dose of FSH was 1 ampule 
(= 75 IU) per day. The first increase in dose by a Y, ampulelday was based 
on absence of a follicle;o,1 0 mm in diameter after 14 days. Thereafter, the 
dose was increased by a Y, ampule/day every 7 days if an ovarian response 
was lacking. If a sufficient ovarian response was observed, the dose was 
kept constant until the administration of hCG. No luteal support was 
provided. 
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Step-down protocol: The starting dose of FSH was 2 ampules (~150 IU) 
per day_ The first decrease in dose by a Y, ampule/day was based on 
visualization of at least 1 follicle:2:1 0 mm in diameter. The initial dose was 
increased by a y, ampule/day if an ovarian response remained absent after 
5 days. If follicular growth remained absent over the following 10 days (2 
incremental steps of a Y, ampule/day), further medication was withheld 
and the cycle was cancelled. A further dose decrease, each time by a 
y, ampule/day, was performed every 3 days to a minimum dose of 
1 ampule/day if follicular growth continued. This dose was sustained until 
the day hCG could be administered. No luteal support was provided. 
Data analysis: Before initiation of the study, power calculations were 
performed to determine the required number of patients for the detection 
of differences in serum FSH and E2 concentrations and number of dominant 
follicles on the day of hCG administration, comparing both dose regimens. 
Based on the literature and our previous studies (Schoot et a/., 1995; van 
Dessel et a/., 1995) differences were estimated to be 30%. This difference 
was calculated to be apparent with at least 12 patients in each group. 
Values given are mean ± SO unless stated otherwise. The P values 
given are two-sided, and 0.05 was considered the limit of statistical 
significance. Differences between patient groups were tested using the 
Mann-Whitney test, Student's t-test, or Fisher's exact test. The distribu-
tion of ovarian follicles was arbitrarily classified in categories according to 
size (10-12, 12-16, and :2:16 mmL as described previously (van Santbrink 
et a/., 1995b). Ovulation after hCG administration was determined by the 
collapse of the dominant follicle on TVS and mid-luteal P concentrations. 
Pregnancy diagnosis was confirmed by a positive urinary pregnancy test 
(hCG, > 25IU/L), and ongoing pregnancy was confirmed by sonographic 
evidence of an intrauterine gestational sac and fetal heart beat. Patients 
attending our clinic within 2 weeks after the last administration of 
gonadotropins with serious abdominal discomfort, sonographic evidence 
of grossly enlarged ovaries, and increased quantities of free abdominal 
fluid, were reported to be suffering from ovarian hyperstimulation syn-
drome. 
4.3.3 Results 
Thirty-seven normogonadotropic patients with clomiphene-resistant 
anovulation entered the study protocol. After randomization, 19 (51 %) 
patients received exogenous FSH treatment according to a low-dose 
step-up regimen, and 18 patients received a step-down dose regimen. 
Patient characteristics of both groups are shown in Table 7. The groups 
did not differ in any of the characteristics shown. 
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Table 7 Initial patient characteristics (median and range) of 37 normo~ 
gonadotropic clomiphene-resistant oligo- or amenorrheic infertile women 
treated with urinary FSH for ovulation induction. Patients were randomized for 
low-dose step-up or a step-down dose regimens. 
n 
Age (vrs) 
BMI (kg/m') 
Infertility duration (vrs) 
Amenorrhea (%) 
Primary infertility (%)8 
Serum hormone concentrationsb 
LH (lUlL) 
FSH (lUlL) 
E, (pmoI/L) 
T (nmoI/L) 
AD (nmoI/L) 
SHBG (nmol/Li 
Transvaginal ultrasonography: 
Mean ovarian volume (mL) 
Mean follicle number per ovary 
Total stroma countC 
Low-dose step-up 
19 
28 (20-35) 
26 (19-40) 
3 (2-5) 
26 
63 
5.6 (1.5-15.4) 
4.9 (2.7-9.0) 
238 (97-378) 
2.1 (1.3-4.6) 
15.4 (8.5-30.4) 
32 (10-128) 
8.5 (4.0-14.9) 
12.5 (1.5-15.0) 
4 (2-6) 
Step-down 
18 
30 (23-401 
25 (18-41) 
3 (2-7) 
33 
61 
5.8 (2.7-13.8) 
4.5 (2.2-6.8) 
250 (75-864) 
2.2 (1.4-4.3) 
13.3 (9.3-32.8) 
47 (20-164) 
11.3 (5.7-18.4) 
14.3 (5.5-15.0) 
4 (2-5) 
aAbsence of previous pregnancies in the present relationship> 1 year. 
bBlood samples taken at random in month preceding the study cycle. 
C Scored on a scale from 1 (normal) to 3 (severely increased) and added for both ovaries. 
In both groups one patient dropped out early due to extensive vaginal 
bleeding during gonadotropin treatment. Cancellation due to ovarian 
hvperresponse (more than 3 follicles ;0:16 mm in diameter on the day of 
hCG administration) did occur once in the low-dose step-up regimen. 
Seventeen patients in both groups received hCG. One patient in each group 
presented with low luteal P concentrations « 1 0 nmoIlL), suggesting 
absence of ovulation. 
Clinical treatment outcome is presented in Table 8. The median first 
day of ovarian response monitored by TVS in the low-dose step-up group 
was treatment day 11 (range, 5 to 33) vs. day 5 (range, 3 to 13) in the 
step-down group (P<O.OO1). The median day of administration of hCG in 
the low-dose step-up group was treatment day 20 (range, 8 to 42) vs. 10 
(range, 5 to 17) in the step-down group (P=0.001). In the low-dose 
step-up group, 7 patients (39%) achieved a preovulatory follicle using not 
more than 1 ampule/day of urinary FSH. In the step-down group, the initial 
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Table 8 Clinical outcome of 35 normogonadotropic clomiphene-resistant oligo-
or amenorrheic infertile women treated with urinary FSH for ovulation induction. 
Patients were randomized for a low dose step-up (n = 18) or a step-down dose 
regimen (n ~ 17). 
Low-dose step-up Step-down P= 
Median duration of treatment (days) 18 (7-41) 9 (4-16) 0.003 
Median # of ampules used per cycle 20 (7-69) 14 (7-33) NS 
Daily FSH change (lUlL) from the day +0.6 -1.3 <0.001 
of ovarian response until hCG. ( +2%/day) (-5%/day) 
Patients with decreasing late- 6 (39%) 17(100%) <0.001 
follicular phase FSH levels 
Mono-follicle growtha (n =) 10 (56%) 15 (88%) 0.04 
Patients with E2 within normal 
pre-ovulatory range (500-1500 pmol/L) 6 (33%) 12 (71%) 0.03 
Cycles cancelled (n =) 2 
Overall ovulation rate 84% 89% 
Ongoing pregnancies (n =) 2 5 
Multiple pregnancies (n =) 0 0 
Abortion (n =) 1 0 
Tubal pregnancy (n ~) 1 0 
Ovarian hyperstimulation (n =) 0 0 
80efined as 1 follicle ~16 mm on the day of hCG administration. 
dose of 2 ampuleslday was sufficient to induce ovarian response within 
5 days in 14 (78%) patients. 
Median serum FSH concentrations on the day treatment was started 
did not differ in both groups, and were higher on the first day of ovarian 
response, as determined by ultrasound, in the step-down group (6.3IU/l 
[range, 4.7 to 10.2 lUll] vs. 5.4 )U/l [range, 3.4 to 9.5 lUll]; P = 0.04; 
Figure 12). From the day of ovarian response until the day of hCG 
administration, FSH concentrations showed an increase in 11 (61 %) 
cycles in the low dose step-up group, whereas in the step-down group, 
FSH concentrations showed a decrease in all cycles (P<0.001). The low 
dose step-up group exhibited a median increase in serum FSH during the 
late follicu)ar phase of 0.6 )U/l (range, 2.0 to -4.3 lUll) per day (= 2% 
increase per day), whereas in the step-down group, FSH concentrations 
decreased during the same period (1.3 )U/l [range, 0.2 to 5.0 lUll] per 
day [= 5% decrease per day; Figure 12]). Differences between the groups 
in changes in serum FSH during the late follicular phase were highly 
significant (P< 0.001). Patients treated according to the low-dose step-up 
protocol with decreasing late follicular phase serum FSH concentrations 
exhibited monofollic)e growth in 5 (71 %) cases, whereas in the group with 
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Figure 13 Distribution of serum E2 levels (upper panel) and number of follicles 
~12 mm diameter (lower panel) on the day of hCG administration in a group of 
35 normogonadotropic clomiphene-resistant oligomenorrheic or amenorrheic 
infertile patients treated after randomization according to a low-dose step-up 
(+; n = 18) or a step-down dose regimen (0; n == 17) for induction of ovulation. 
Significant correlation could not be observed between serum FSH change in the 
late follicular phase (between the day of ovarian response and the day of hCG 
administration) and the above-mentioned parameters in the total study group 
or in both subgroups. 
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Figure 14 Distribution of number of ovarian follicles (arbitrarily classified as 
12-16 mm diameter [upper panel], and ~16 mm [middle panel) and serum E2 
levels (lower panel) on the day of hCG administration in 35 normogonadotropic 
clomiphene-resistant oligo- or amenorrheic infertile women randomized for a 
step-down dose regimen (n = 1 7) or a low-dose step-up regimen (n = 1 8) for 
induction of ovulation with urinary FSH. The asterisk indicates the significant 
difference (P = 0.04) in percentage of patients (56% vs. 88%) presenting with 
monofollicular cycles (1 follicle ~16 mm only) comparing both treatment 
schedules. The percentage of patients (33% vs. 71 %) with normal pre*ovula-
tory serum E2 1evels (500-1500pmoIlL) is also significantly (P ~ 0.03) different. 
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increasing late follicular phase serum FSH concentrations, there were 5 
(45%) patients exhibiting monofollicular growth (P = NS). No significant 
correlation was observed between absolute individual changes in serum 
FSH concentrations in the late follicular phase (between the day of ovarian 
response and the day of hCG administration) and serum E2 concentrations 
or number of follicles (,,12 mm in diameter) on the day of hCG administra-
tion in the total study group or in both subgroups (Figure 13). 
The distribution of follicles (arbitrarily classified in size categories of 
12-16 and ,,16 mm in diameter) on the dayof hCG administration is shown 
in Figure 14. Medium-sized follicles of 10-16 mm in diameter were absent 
in 22% and 29% of low-dose step-up and step-down cycles, respectively 
(P= NS). Ovarian volumes on the day of hCG administration and 3 days 
thereafter showed no differences between both groups (data not shown). 
The median increase in serum E2 concentrations from the day of ovarian 
response until day of hCG administration was 179 pmol/L (range, 33 to 
742 pmol/L) per day in the lOW-dose step-up group and 250 pmoliL (range, 
23 to 1273 pmol/L) per day in the step-down group (P= NS). 
In the step-up group, one pregnancy ended in an early miscarriage at 6 
weeks, and one appeared to be a tubal pregnancy which had to be removed 
by laparoscopy. The ongoing pregnancy rate in the step-up group was 
13%, compared with 31 % in the step-down group. 
4.3.4 Discussion 
Knowledge regarding the interplay between serum FSH concentrations 
and follicle growth during the normal menstrual cycle has increased, and 
the process of selection of a single dominant follicle has been recognized 
to be dependent on decreasing FSH concentrations during the late-follicular 
phase (Zeleznik et al., 1985; Lolis et al., 1995). In contrast, increasing 
serum FSH concentrations in the late follicular phase have been described 
during conventional step-up regimens for induction of ovulation, even 
using a low-dose step-up regimen (Dale et al., 1993). Step-up regimens 
ignore the concept that the FSH-threshold should be surpassed for a limited 
period of time only (a narrow window), sufficient to allow a single follicle 
to gain dominance (Brown et al., 1978; Fauser et al., 1997a). As 
complications of gonadotropin induction of ovulation, such as ovarian 
hyperstimulation and multiple pregnancy, are related to multiple follicle 
development (Blankstein et al., 1987), it may be worthwhile to focus on 
various dose regimens and resulting patterns in serum FSH concentrations. 
In some ovulation induction studies (Dale et al., 1993), late follicular phase 
steady state serum FSH concentrations were observed during low-dose 
step-up regimens. Moreover, preliminary data suggest that decreasing 
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serum FSH concentrations may occur due to negative estrogen feedback 
action in some patients (White et al., 1995) or i.v. low-dose step-up FSH 
administration (van der Meer et al., 1996). 
Our group has focused on a method of obtaining serum FSH concen-
trations during gonadotropin induction of ovulation that more closely mimic 
physiology (Fauser, 1994). These studies have shown that the late 
follicular phase serum FSH profile during a step-down dose regimen with 
initial doses of 2 ampules per day and decreasing steps of a Y, ampule per 
day closely resembles FSH serum concentrations during the spontaneous 
cycle (Schoot et al., 1995; van Dessel et al., 1995), and that treatment 
outcome is at least comparable to that using lOW-dose step-up protocols 
(van Santbrink et al., 1995b). To substantiate potential differences, we 
compared the step-down induction regimen with a low-dose step-up 
protocol in a prospective randomized trial. The results obtained indicate 
that in the step-down group, serum FSH concentrations decrease in the 
late follicular phase in all patients (median 5% per day), whereas in the 
low-dose step-up group, individual serum FSH concentrations decrease in 
only 39% of patients (P< 0.001). The small number of patients (39%) in 
the low-dose step-up group that present with decreasing late follicular 
phase serum FSH concentrations consists of patients that in the majority 
of cases (71 %) exhibit monofollicle growth; the 'good-responders'. Con-
sistent with pharmacokinetic stUdies (Mizunuma et al., 1 991; Mannaerts 
et al., 1993), the overall median serum FSH concentration in the low-dose 
step-up group remains fairly stable in the late follicular phase. Another 
study in which exogenous FSH was replaced by pulsatile administration 
of gonadotropin releasing hormone (GnRH) when dominant follicle growth 
was first recognized showed that multiple follicle growth was minimized, 
and a low multiple pregnancy rate could be obtained (Kuwahara et al., 
1995). The decrease in serum FSH during step-down ovulation induction 
in a protocol that combined exogenous gonadotropins with GnRH agonists 
showed a more pronounced median decrease of 10% per day (Schoot et 
al., 1995) compared to the 5% daily decrease demonstrated in the present 
study. In a study in which patients were treated according to a low-dose 
step-up protocol using i.v. gonadotropin administration with and without 
pituitary down-regulation by GnRH agonists (van der Meer et al., 1996), 
the effect was reversed; in the group treated with GnRH agonists, FSH 
serum concentrations were stable, whereas a minimal decrease occurred 
in the group treated with gonadotropins alone. This may be related to the 
changes in endogenous FSH production in non-suppressed patients. All of 
the above-mentioned observations favor a limited role for Ez in late follicular 
FSH patterns in gonadotropin-stimulated cycles. 
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We observed more monofollicle cycles (88% vs. 56%) and more 
preovulatory E2 serum concentrations in the physiological range (71 % vs. 
33%) in the step-down group than in the low-dose step-up group. This 
may coincide with reduced chances for multiple pregnancy and ovarian 
hyperstimulation (Haning et a/., 1983; Siankstein et a/., 1987). The 
reported percentages of monofollicle cycles in low-dose step-up studies 
vary substantially due to different criteria used for defining monofollicular 
growth and cycle cancellation. The small subgroup of patients in the 
step-down protocol with very high late follicular phase serum E2 concen-
trations (patients that hyperstimulate with the starting dose) may respond 
better on a lower starting dose of gonadotropins. Another feature observed 
in this study is that the step-down group ovulated after a shorter induction 
time (9 vs. 18 days). Using a low-dose step-up protocol, patients may 
initially be exposed to serum FSH concentrations below the threshold for 
an extended period of time, resulting in a longer treatment period than 
strictly necessary. The treatment duration and number of ampules used 
in the low-dose step-up regimen in our study are comparable to data 
reported previously (Suvat et a/., 1989; White et a/., 1996). Few other 
studies have reported the application of exogenous FSH in a step-down 
fashion for induction of ovulation (Mizunuma et a/., 1991; Steinkampf et 
a/., 1993). The inclusion criteria used and a rigid step-down protocol render 
it difficult to draw conclusions from these studies. A large randomized 
study comparing conventional step-up and step-down regimens (initial 
dose 3 ampules/day) has only appeared in abstract form (Steinkampf et 
a/., 1993). 
In conclusion, our findings suggest that in a group of normogonado-
tropic clomiphene-resistant anovulatory infertile women, induction of 
ovulation using a step-down gonadotropin dose regimen results in com-
parable ovulation and pregnancy rates and a much shorter induction period 
than that required with a lOW-dose step-up regimen. This may bring health 
economic benefits (more ovulations per given period of time). In addition, 
the late-follicular phase serum FSH profile is more physiological and results 
in more monofollicular cycles and more cycles in which E2 concentrations 
are within the normal preovulatory range. These observations may have 
important implications for the risk of ovarian hyperstimulation and multiple 
pregnancy. 
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5 
General Discussion and 
Conclusions 
The first objective of this thesis was to evaluate the role which FSH plays 
in the process of follicle recruitment and subsequent selection of a single 
dominant follicle. We studied this issue during the normal menstrual cycle 
in healthy volunteers and in anovulatory infertile patients during gonadot-
ropin induction of ovulation using a decremental dose regimen by frequent 
monitoring of follicle growth with the use of transvaginal sonography (TVS) 
in combination with serum blood sampling. 
In a group of 16 strictly selected normal weight volunteers with regular 
menstrual cycles a major individual difference in FSH-threshold (2%-fold) 
for stimulation of follicle development was observed (see also Schipper et 
a/., 1998a). As maximum early follicular-phase FSH serum concentrations 
or FSH-decrease did not correlate with any patient or cycle characteristic, 
this finding may suggest major interindividual differences in FSH threshold. 
Variation may suggest individual differences in autocrine or paracrine 
modulation of FSH action during the process of follicle recruitment. During 
the late follicular phase, decreasing serum FSH concentrations in combin-
ation with an increasing sensitivity of the dominant follicle for FSH 
stimulation, probably modulated by intra-ovarian factors, facilitates the 
process of selection of a single dominant follicle (Schipper et a/., 1998b). 
Within the cohort of follicles, recruited by early follicular-phase rise in 
serum FSH concentration, each follicle has its individual developmental 
stage. The developmental stage determines the amount of FSH stimulation 
needed to prevent atresia, the FSH threshold. When FSH serum concen-
trations are decreasing, less mature follicles will go into atresia, while a 
single dominant follicle will continue its growth. We observed an associa-
tion between the magnitude of decrease in early follicular phase endo-
genous serum FSH concentrations and the following E2 serum rise, 
indicating that the duration of FSH stimulation is a major determinant for 
intra-ovarian granulosa cell aromatase activity, resulting in increased E2 
production when FSH stimulation is prolonged. A strong correlation 
between the first day a dominant follicle could be determined by sonog-
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raphy and the start of a rise in serum E2 concentrations indicates that 
transvaginal sonography is an accurate tool to monitor follicle develop-
ment. 
The patient group suffering from anovulatory infertility can be divided 
into a group with clear disturbances in gonadotropin serum concentrations 
(hypogonadotropic or hypergonadotropic amenorrhea) and a group with 
normal gonadotropins (normogonadotropic amenorrhea). A substantial 
part of patients in the latter group is described as polycystic ovary 
syndrome (peas), Because a clear controversy exists in the literature 
regarding endocrine and sonographic criteria used to define peas, we 
started to evaluate and compare criteria most frequently used in literature. 
A more consistent definition of inclusion criteria used to determine 
peas may lead to better understanding of this heterogeneous entity. In 
addition, standardized initial screening of normogonadotropic anovulatory 
infertile patients - regardless of whether the criteria fit peas diagnosis -
may help to predict outcome of ovulation induction (medication and doses 
needed, chances for success or complications) and long-term health risks. 
A study by our group (Imani et al., 1998) has indicated that it may be 
possible to predict treatment response, during clomiphene-citrate ovula-
tion induction in anovulatory normogonadotropic infertility, by initial 
screening of patient characteristics and cycle history; this approach will 
be the focus of a subsequent thesis from our group. 
We observed considerable overlap between various parameters used in 
the literature to define peas and concluded that, after defining strict 
cut-off levels for sonographic and endocrine parameters in a control 
popUlation, polycystic ovaries on ultrasound suffered from poor predictive 
value for endocrine abnormalities (hyperandrogenicity andlor elevated LH 
serum concentrations) used to define peas. So after all, the polycystic 
sonographic image of the ovaries may not be a very important parameter 
in anovulatory infertility. Another important issue is identification of initial 
patient characteristics, that can predict treatment response to gonado-
tropin induction of ovulation. This may help to further classify anovulatory 
infertile women and add to the ongoing discussion regarding criteria used 
to define peas. Accordingly, initial clinical, endocrine and sonographic 
characteristics were evaluated in a group of normogonadotropic amenor-
rheic infertile women with clomiphene-citrate resistance or failure treated 
according to a step-down dose regimen for induction of ovulation. Results 
of this preliminary study suggest that initial patient characteristics like 
obesity, ovarian aging (low basal E2 serum concentrations and small initial 
ovarian volume), polycystic ovaries and elevated serum androgens 
(DHEAS and FAil may be associated with impaired treatment response. 
70 
GENERAL DISCUSSION AND CONCLUSIONS 
Future prospective, follow-up studies (imani et a/., in preparation) will have 
to prove whether this approach is clinically useful. 
Complications of induction of ovulation using exogenous gonadotropins 
in the group of normogonadotropic clomiphene-resistant oligomenorrheic 
or amenorrheic infertile women are a cause of major concern. These 
complications - mainly ovarian hyperstimulation and multiple pregnancy 
- are both reported to be correlated with late follicular phase FSH 
accumulation (Ben Rafael et a/., 1986) and multifollicular development 
(Blankstein et a/., 1987). In an attempt to reduce these complications 
alternative gonadotropin treatment schedules have been developed. The 
conventional step-up regimen has been modified to a 'low-dose' step-up 
regimen, which resulted in a decrease in complication rates but in some 
studies at the cost of lower pregnancy rates and an extended period of 
stimulation was necessary (Hull, 1991). Our group developed a new 
induction schedule trying to mimic physiological follicular phase serum 
FSH concentrations: the step-down dose regimen. Results indicated a 
more physiologic FSH serum profile, but a wide range in interpatient 
variability was observed. The protocol was modified to a low-dose 
step-down protocol (each step-down with Y, ampule/day) and a starting 
dose of 2 ampules/day. The first step-down was based on the identification 
of a dominant follicle by sonography and the minimum dose was 1 
ampule/day. GnRH agonist pretreatment was abandoned because ex-
pected normal range serum E2 concentrations would not result in prema-
ture luteinization and interference with endogenous gonadotropin release 
did not seem to have clinical implications. We conducted a clinical 
experience trial to test the step-down dose regimen for induction of 
ovulation as a safe and effective treatment alternative. This could be 
confirmed in a study in which a group of normogonadotropic clomiphene-
resistant oligomenorrheic or amenorrheic infertile women was treated. The 
new step-down dose regimen appeared to be a clinically safe and effective 
treatment alternative (a much shorter induction period was needed and 
comparable ovulation and pregnancy rates were established). 
A second step in the trial was to compare the step-down dose regimen 
to a low-dose step-up regimen for induction of ovulation in a randomized 
prospective study. This is the first reported randomized comparison 
between two different regimens for gonadotropin induction of ovulation. 
The lOW-dose step-up regimen is the most generally used gonadotropin 
induction schedule for ovulation induction. The comparison between the 
step-down and a low-dose step-up dose regimen in a group of normo-
gonadotropic oligo- or amenorrheic clomiphene-resistant infertile women 
resulted in a significantly shorter induction period in the step-down group, 
while ovulation and pregnancy rates were at least comparable. In addition, 
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late-follicular phase FSH serum profile in the step-down group resembled 
physiology more closely, resulting in more monofollicular cycles and more 
cycles with serum E2 concentrations within the pre-ovulatory range. In 
contrast, steady-state follicular phase serum FSH concentrations were 
observed during low-dose step-up protocols. These observations may have 
implications for chances of ovarian hyperstimulation and multiple pregnan-
cies. A comparative multi-center trial to study the clinical outcome 
following both regimens is conducted in France at the moment. Although 
the step-down dose regimen may seem a new treatment alternative for 
all patients treated with exogenous gonadotropins for induction of ovula-
tion, one should be cautious with direct clinical introduction. The following 
reasons should be considered: (1) for about 30% of all patients a fixed 
gonadotropin dose of 1 ampule/day is sufficient to stimulate dominant 
follicle development; (2) intensive monitoring is recommended (every 2-3 
days) because there are hyper-responders on a 2 ampules/day starting 
dose; (3) monitoring a step-down dose regimen induction cycle requires 
more experience and skills. Therefore, step-down regimens potentially give 
rise to higher chances for complications in inexperienced hands. 
Combining these study results into a safe and effective protocol to treat 
a new patient using exogenous gonadotropins for induction of ovulation, 
could be an initial 'dose-finding' cycle according to a low-dose step-up 
protocol. In this way patients exhibiting ongoing follicle growth using a 
starting dose of 1 ampule/day - the 'good responders'- can be identified. 
In patients not responding with ongoing follicle growth the daily dose 
should be increased. The second cycle is initiated according to a step-down 
dose regimen in these patients with a starting dose Y, ampule above the 
effective dose in the preceding low-dose step-up cycle. If no step-up has 
been necessary (the patient requires no more than 1 ampule/day to develop 
a pre-ovulatory follicle) the fixed dose regimen can be repeated. In this 
way, easy (low FSH threshold) and poor (high FSH threshold) responders 
are separated and complication rates may be lowered (In Preparation). It 
may also become possible, as discussed earlier, to predict whether a 
patient belongs to one group or the other, on the basis of initial screening 
characteristics (Imani et a/., In Preparation). 
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Summary I Samenvatting 
Chapter 1 
This chapter aims at providing the reader with a brief overview of the 
history and development of knowledge regarding the function of the 
human ovary. It describes in more detail what is known about physiologic 
processes, regulating human follicle growth and selection of a single 
dominant follicle. Disturbances in follicle growth and possible treatment 
modalities in normogonadotropic clomiphene-resi&tant anovulatory 
women are discussed. 
Chapter 2 
To evaluate the role of FSH in follicle growth and selection of a single 
dominant follicle a group of 16 strictly regularly menstruating healthy 
women are studied. Daily blood samples are drawn and sonographic 
monitoring is performed every other day. Findings are a 2 Jf,-fold difference 
in early follicular maximum serum FSH concentrations indicating a wide 
range in FSH threshold between individuals. The first day a dominant 
follicle could be recognized by TVS was strongly correlated with the first 
day serum E2 starts to rise. Because E2 is produced mainly by the dominant 
follicle ultrasonography proves to be a reliable tool to monitor ovarian 
response. A negative association was observed between the decrease of 
serum FSH during the late follicular phase and the serum E2 increase: FSH 
may induce E2 biosynthesis in dominant follicle granulosa cells. 
Chapter 3 
Section 3. 1 A lack of consensus on criteria used for pcas diagnosis lead 
to this study in which we investigated the predictive value of polycystic 
ovaries diagnosed by TVS for endocrine signs of pcas. First we set strict 
cut-off levels for endocrine and sonographic currently-used parameters in 
a control population. The use of these upper limits of normal in a group of 
250 normogonadotropic oligomenorrheic or amenorrheic women visiting 
our fertility clinic resulted in 217 (66%) patients with polycystic ovaries 
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on ultrasound (defined as increased mean ovarian volume and/or mean 
follicle number per ovary), whereas 120 (36%) patients exhibited elevated 
serum androgens (increased serum AD and/or T) and 155 (47%) showed 
elevated LH concentrations. There was extensive overlap between these 
groups but limited predictive value of sonographic parameters for abnormal 
serum hormone concentrations. 
Section 3.2 The objective of this study was to evaluate classification 
criteria in use for defining the normogonadotropic clomiphene-resistant 
oligomenorrheic or amenorrheic women with regard to their usefulness as 
predictor of treatment response in case of induction of ovulation using 
exogenous gonadotropins. Obesity, ovarian aging (low basal serum E2 
concentrations and small initial ovarian volume), polycystic ovaries and 
elevated serum androgens (DHEAS and FAil were observed to be associ-
ated with impaired treatment response. More gonadotropins were needed 
and higher cancellation rates were observed. 
Chapter 4 
Section 4. 1 Clinical experience with a step-down regimen for induction 
of ovulation with exogenous gonadotropins in a group of 82 normogon-
adotropic clomiphene-resistant anovulatory infertile patients is reported. 
In a total of 234 cycles a median treatment period of 11 days and a total 
of 14 ampules of gonadotropin were needed. Monofollicular growth was 
observed in 131 (62 %) cycles while in 208 (98 %) cycles not more than 
2 follicles :0:16 mm diameter were present. A total of 37 pregnancies 
occurred of which 2 were twins and 1 was a triplet (multiple pregnancy 
rate: 8%). The pregnancy rate per cycle was 17% and the cumulative 
pregnancy rate after 7 months was 47%. The abortion rate was 19%. 
There were 4 cases of mild ovarian hyperstimulation, of which none 
became pregnant. The present study shows that the applied step-down 
regimen for gonadotropin induction of ovulation is a safe and effective 
treatment alternative for patients with clomiphene-resistant anovulation. 
Section 4.2 To compare a low-dose step-up to a step-down regimen for 
induction of ovulation in a group of normogonadotropic clomiphene-resis-
tant anovulatory infertile patients, this prospective randomized study was 
performed. The objectives were to assess potential differences in treat-
ment duration and dose, ovarian stimulation (serum FSH concentrations) 
and response (serum E2 concentrations and follicle number and size). 
Thirty-seven patients were included and randomized. The duration of the 
treatment period was reduced by 50% in the step-down group compared 
to the low-dose step-up group (9 vs. 18 days), the amount of gonadotropin 
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needed per cycle did not differ significantly (14 vs. 20 ampules). All 
patients in the step-down group showed a late-follicular FSH decrease 
compared with only 35% in the low-dose step-up group. Monofollicular 
growth on the day of hCG administration was observed in 88 % of the 
step-down group versus 56% in the low-dose step-up group. Serum E2 
concentrations on the day of hCG administration were in the normal 
pre-ovulatory range in 71 % of the patients in the step-down group while 
only in 33% of patients in the low-dose step-up group. In conclusion this 
study suggests that in a group of normogonadotropic clomiphene-resistant 
anovulatory infertile patients induction of ovulation according to a step-
down dose regimen results in at least comparable ovulation and pregnancy 
rates while a much shorter induction period is needed compared to a 
low-dose step-up regimen. This may support health economic benefits 
(more ovulations per given period of time). In addition, late follicular phase 
FSH serum profile resembles physiology more closely resulting in more 
monofollicular cycles and more cycles with serum E2 concentrations in the 
normal pre-ovulatory range. This observation may have important impli-
cations for chances of ovarian hyperstimulation and multiple pregnancy. 
Chapter 5 
This chapter aims at providing the reader with an overview of study results 
presented in this thesis, and these findings are discussed in the perspective 
of recent knowledge in this field including future perspectives. 
SAMENVATTING (DUTCH) 
Hoofdstuk 1 
Dit hoofdstuk geeft een overzicht van de historie en ontwikkeJing van 
kennis betreffende de functie van de menseJijke eierstok. Fysiologische 
processen die een rol spelen bij follikelgroei en de selectie van de dominante 
follikel worden beschreven. Tevens worden stoornissen in follikelontwik-
keJing en mogeJijkheden tot behandeling hiervan, met de nadruk op 
normogonadotrope clomifeen-resistente anovulatie, besproken. 
Hoofdstuk 2 
Om de rol van FSH ten aanzien van follikelgroei en selectie van de 
dominante follikel nader te onderzoeken wordt een groep van 16 gezonde 
strikt regulair menstruerende vrijwilligsters onderzocht. Er wordt dageJijks 
bloed afgenomen en om de dag transvaginale echografie verricht 
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gedurende een volledige cyclus. In de vroeg folliculaire fase wordt een 
2 %-voudig verschil gevonden in maximale FSH serum waarde. Dit geeft 
aan dat er een groot inter-individueel verschil bestaat in FSH drempel-
waarde, die overschreden moet worden om follikelgroei te induceren. De 
eerste dag dat er echografisch een dominante follikel kan worden onder-
scheiden is sterk gecorreleerd met de eerste dag dat er een serum E2 spiegel 
stijging plaatsvindt. Omdat het serum E2 hoofdzakelijk door de dominante 
follikel wordt geproduceerd kan geconcludeerd worden dat echografie een 
betrouwbaar middel is om ovariele respons te monitoren. Er wordt een 
negatieve correlatie gevonden tussen de mate van FSH daling in de 
laat-folliculaire fase en de mate van E2 stijging die hierop voigt. FSH lijkt 
direct de E2-biosynthese te induceren in de dominante follikel, terwijl 
follikelgroei op dat moment steeds minder afhankelijk van FSH lijkt te 
worden. 
Hoofdstuk 3 
Paragraaf 3. 1 Het polycysteus ovarium syndroom (peOS) is een vee I 
besproken maar slecht gedefinieerd ziektebeeld. Dit was de aanleiding om 
deze studie te verrichten, waarin wij trachten meer duidelijkheid te krijgen 
over de criteria die meestal in de literatuur worden gebruikt om peos te 
definieren, en in de mate waarin deze criteria onderling samenhangen. Er 
wordt gekeken of de mate van afwijking van echografische peOS-parame-
ters iets zegt over biochemische peos karakteristieken zoals beschreven 
in de literatuur. Hiertoe hebben wij eerst in een controle groep van strikt 
regelmatig menstruerende vrijwilligsters normaal waarden bepaald voor 
echografische en endocriene peos parameters. Deze normaalwaarden 
werden geprojecteerd op de studiegroep van 250 normogonadotrope 
infertiele patienten met een oligo- of amenorrhoea. Dit resulteerde in 217 
(66%) patienten met echografisch polycysteuze ovaria (gedefinieerd als 
toegenomen gemidC:eld ovarieel volume en/of toegenomen follikel aantal 
per ovarium). 120 (36%) patienten met verhoogde serum androgenen 
(toegenomen AD en/of T) en 155 (47%) patienten met verhoogde LH 
serum waarden. Er wordt uitgebreide onderlinge overlap tussen deze 
criteria gevonden, maar beperkte predictieve waarde van echografische 
parameters voor endocriene peos criteria. 
Paragraaf 3. 2 Het doel van deze stu die is de classificatie criteria die voor 
onderverdeling van normogonadotrope clomifeen-resistente amenorrhoea 
worden gebruikt te evalueren voor wat betreft voorspellende waarde voor 
behandelingsrespons tijdens ovulatie-inductie met behulp van exogene 
gonadotrofinen. Overgewicht, ovariele veroudering (laag basaal E2 en/of 
klein initieel ovarieel volume). polycysteuze ova ria en verhoogde serum 
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androgenen (DHEAS en FAil zijn gecorreleerd met een verminderde 
behandelingsrespons. Er zijn meer ampullen gonadotroline per eyelus nodig 
en een hoger aantal cycli moet voortijdig worden algebroken. 
Hoofdstuk4 
Paragraaf 4. 1 Dit hoofdstuk behandelt de klinische ervaring met het 
'step-down' doseringssehema voor ovulatie inductie, zoals in Rotterdam 
ontwikkeld. Een groep van 82 normogonadotrope elomifeen-resistente 
infertiele vrouwen werd gedurende de periode 1991 tot 1993 behandeld, 
met een totaal van 234 ovulatie-inductie eycli. De gemiddelde behan-
delingsduur was 11 dagen, waarin 14 ampullen gonadotroline gebruikt 
werden. Er was een ovulatie aantoonbaar in 91 % van de gestartte cyeli 
en hiervan waren er 131 (62%) monofolliculair en 208 (98%) met niet 
meer dan 2 follikels ?16 mm diameter op de dag van hCG toediening. 
Totaal kwamen er 37 zwangerschappen tot stand waarvan 2 tweeling en 
1 drieling zwangerschap (meerling percentage 8%). Zwangerschaps per-
centage per cyclus was 17% en het cumulatieve percentage na 7 maanden 
was 47%. Abortus percentage was 19%. Er waren 4 gevallen van milde 
ovariele hyperstimulatie (zander opname) waarvan niemand zwanger bleek 
te zijn. Deze studie toont aan dat het toegepaste step-down schema voor 
ovulatie inductie een veilig en effectiel alternatief is voor patienten met 
een normogonadotrope clomifeen-resistente amenorrhoea. 
Paragraaf 4.2 In deze gerandomiseerde studie wordt het step-down 
protocol voor ovulatie inductie met gonadotrofinen vergeleken met het low 
dose step-up protocol in een groep van patienten met een normogonadot-
rope elomifeen-resistente amenorrhoea. Het initiele studiedoel omvatte het 
vastleggen van potentiele verschillen in behandelingsduur en dosis, 
ovariele stimulatie (serum FSH spiegels) en ovariele respons (serum E2 en 
follikelaantal en lollikel grootte). Er worden 37 patienten geincludeerd en 
gerandomiseerd waarvan 18 in de step-down groep. De behandelingsduur 
is in de step-down graep gereduceerd met 50% verge Ie ken met de low 
dose step-up groep (9 dagen vs. 18 dagen), het aantal benodigde ampullen 
gonadotrofine verse hilt niet significant (14 amp. vs. 20 amp.). In de 
step-down groep vertonen aile patienten een dalende FSH spiegel in de 
laat-folliculaire fase terwijl dit slechts in 35 % van de patienten in de low 
dose step-up groep word gevonden. Serum E2 spiegels op de dag van hCG 
gift zijn bij 71 % van de patienten in de step-down graep binnen de normale 
pre-ovulatoire grenzen terwijl dit slechts bij 33% van de patienten in de 
low dose step-up graep kan worden vastgesteld. Monofolliculaire groei op 
de dag van hCG gift wordt bij 88% van de patienten in de step-down groep 
gezien terwijl dit in de low dose step-up groep in 56% van de gevallen 
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gevonden wordt. Concluderend kan over deze studie worden gezegd dat 
in een groep van patienten met een normogonadotrope clomifeen-resis-
tente amenorrhoea, die wordt behandeld met ovulatie inductie middels 
exogene gonadotrofinen waarin een step-down en een low dose step-up 
protocol met elkaar wordt vergeleken, op zijn minst vergelijkbare ovulatie-
en zwangerschaps percentages worden gevonden terwijl er een beduidend 
kortere inductieduur nodig is in de step-down graep. Oit kan duidelijk 
consequenties hebben op het gezondheids-economische vlak (meer ovu-
laties in een zelfde tijdsbestek). Verder laat deze stu die zien dat het laat 
folliculaire FSH profiel in de step·down graep het fysiologisehe profiel beter 
benadert, hetgeen resulteert in meer eycli met E2 serum spiegels in de 
normale pre-ovulatoire range en meer cyeli met monofolliculaire groei. Oit 
kan belangrijke voordelen bieden ten aanzien van de kans op eomplicaties 
als ovariele hyperstimulatie en meerlingzwangerschappen. 
Hoofdstuk 5 
Oit hoofdstuk geeft een overzieht van de studieresultaten van dit 
proefsehrift en probeert deze in het perspectief van de huidige kennis op 
dit gebied te plaatsen. Tevens wordt getracht om met deze resultaten in 
de hand een blik te werpen op toekomstige mogelijkheden. 
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